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Abstract
ATRX is a Rad54 translocase homolog implicated in regulating the epigenetic
environment of heterochromatin, mitosis, and gene transcription. Myelin is a
specialized membrane encompassing axons of neurons, allowing for efficient
propagation of action potentials. CNS myelin arises via oligodendrocyte precursor
cell (OPC) differentiation into myelinating oligodendrocytes (OLs), which then extend
and wrap axons. Myelination is a tightly regulated process, however the
mechanisms involved have yet to fully manifest. Here, we report that ATRX loss
results in hypomyelination due to a defect in OPC differentiation and OL maturation,
as ATRX loss did not affect OPC production, proliferation, or cholesterol
biosynthesis. Additionally, myelin sheath formation was unaffected when ATRX was
lost specifically from OLs, suggesting a non cell-autonomous role of ATRX in
myelination. Clarifying the role of ATRX in myelination presents a novel mechanism
that regulates myelin sheath formation, and findings from this study will benefit future
treatments of myelin disorders, including ATR-X.
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Introduction

1.1 ATRX
1.1.1

The ATRX gene and protein

The alpha thalassaemia mental retardation, X-linked (ATRX) protein is a
chromatin remodeling protein that is a homolog of the radiation mutant 54
(Rad54) translocase (Stayton et al., 1994). The ATRX gene is located on the
long-arm of the X-chromosome (Xq13.3), and contains 36 exons spanning over
300 kilobases (kb) of genomic DNA (Gibbons et al., 1995; Picketts et al., 1996a).
Analysis of the ATRX gene revealed that it encodes at least three alternative
transcripts. Two of the transcripts are the result of an alternative splicing event of
exon 6, resulting in two 10.5 kb mRNA transcripts that are predicted to give rise
to slightly different proteins of 265 and 280 (kilodalton) kDa, respectively. The
third transcript results from a failure to splice out intron 11 of the ATRX gene,
resulting in a truncated isoform of the ATRX protein (ATRXt) (Bérubé et al., 2000;
Garrick et al., 2004). The function of the ATRXt protein has not been fully
elucidated, however it has been found to have binding affinity for the full-length
ATRX protein suggesting that it may be required to regulate ATRX activity at
heterochromatin (Garrick et al., 2004; Bérubé et al., 2005). The full-length ATRX
protein contains two highly conserved domains; a carboxy (C)-terminal
helicase/adenosine

triphosphatase (ATPase) domain

that is

a member

2

Figure 1. The ATRX protein structure and function
A) Representation of the ATRX protein containing two-highly conserved domains
(the ADD DNA binding domain and the Snf2 chromatin remodeling domain), as
well as the areas of the ATRX protein that interact with Daxx, MeCP2 and PML
nuclear

bodies.

B)

Representation

of

the

ATRX

protein

function

at

pericentromeric heterochromatin. The ADD domain interacts with DNA through
recognition of the H3K9me3 and H3K4me0 epigenetic modifications (Dhayalan et
al., 2011; Eustermann et al., 2011; Iwase et al., 2011). ATRX interacts with
DAXX to allow incorporation of H3.3 into nucleosomes of chromatin (Drané et al.,
2010; Goldberg et al., 2010; Lewis et al., 2010; Wong et al., 2010).
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of the sucrose non-fermenting 2 (Snf2) family of proteins, as well as an amino
(N)-terminal

ATRX-DNMT3-DNMT3L

(ADD)

domain

containing

a

plant

homeodomain (PHD)-like zinc finger, and a C2-C2 GATA-like zinc finger domain
(Figure 1A) (Picketts et al., 1998; Xie et al., 1999; Aapola et al., 2000; Argentaro
et al., 2007). On the other hand, the ATRXt protein lacks the C-terminal Snf2
ATPase domain, but retains the N-terminal ADD domain suggesting it may act
primarily at pericentromeric heterochromatin (Bérubé, 2011).
ATRX is a member of the Snf2 subgroup of the switch/sucrose non-fermenting
(SWI/SNF) family of proteins as it contains seven highly conserved collinear
domains of this family, demonstrating its function in ATPase chromatin
remodeling activity (Picketts et al., 1996). SWI/SNF proteins have been shown to
play roles in a vast array of cellular functions including transcriptional elongation,
DNA repair, and regulation of mitosis (Carlson and Laurent, 1994; Eisen et al.,
1995; Picketts et al., 1996).
The ATRX protein also contains an ADD chromatin-binding domain. It has been
found that ATRX can recognize and bind histone tails through various
modifications, including trimethylation on lysine 9 of histone 3 (H3K9me3) and
H3K4me0 (Dhayalan et al., 2011; Eustermann et al., 2011; Iwase et al., 2011). In
addition, in vitro studies have also shown ATRX has the ability to bind to lysine 4
of the histone 3 variant, H3.3 (Wong et al., 2010).
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1.1.2

Cellular functions of ATRX

ATRX is a nuclear protein crucial for the regulation of the epigenetic environment
of heterochromatin, mitosis, and gene transcription. It has been established that
ATRX is required for the proper expression of a subset of genes known as
ancestral pseudoautosomal region (aPAR) genes (Levy et al., 2008). It was
determined that ATRX promotes the expression of aPAR genes through the
incorporation of H3.3 (Levy et al., 2014). ATRX facilitates the incorporation of
H3.3 into nucleosomes of aPAR gene bodies resulting in the relaxation of barrier
structures known as G-quadraplexes. Inhibition of G-quadraplex formation allows
for elongation of RNA polymerase II along the gene body, thus initiating
transcription (Levy et al., 2014). In the absence of ATRX, H3.3 incorporation into
nucleosomes of aPAR gene bodies was diminished, thus allowing for the
formation of G-quadraplexes. These G-quadraplex structures were found to
block, and subsequently stall RNA polymerase II from progressing along the
gene body resulting in a significant decrease of aPAR gene expression (Levy et
al., 2014). These findings reveal a primary role for ATRX in the regulation of
gene expression.
ATRX has been shown to influence gene expression through its interaction with
several factors, including methyl-CpG-binding protein 2 (MeCP2), CCCTCbinding factor (CTCF), and cohesin. Studies have shown that ATRX binds with
MeCP2, CTCF, and cohesin to influence the expression of the H19/Igf2 and
Gtl2/Dlk1 imprinted regions in the postnatal brain. It was determined that MeCP2
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acts as a recruiter for ATRX binding at these sites, as loss of ATRX does not
alter the MeCP2 binding efficiency (Kernohan et al., 2010). On the contrary,
ATRX loss causes a decrease in CTCF and cohesin occupancy at these sites,
resulting in altered expression of H19, Igf2, and many other imprinted genes
(Kernohan et al., 2010). In addition, ATRX and MeCP2 binding influences gene
expression by regulating the chromatin architecture at imprinting control regions.
It was found that binding of ATRX to chromatin through its interaction with
MeCP2, repositions nucleosome placement allowing CTCF binding to these sites
(Kernohan et al., 2014). CTCF binding was found to enable the long-distance
recruitment of enhancer elements to imprinting control regions through its
interaction with cohesin, resulting in an increase in expression of imprinted genes
(Kernohan et al., 2014).
ATRX has also been found to interact with death domain-associated protein
(Daxx) to influence gene expression (Xue et al., 2003; Tang et al., 2004). It has
been shown that the ATRX/Daxx complex exhibits translocase activity, as well as
mononucleosome-dependent ATPase activity (Xue et al., 2003; Tang et al.,
2004); however, this activity was found not to reposition nucleosomes to
influence gene expression, suggesting that the ATRX/Daxx complex regulates
gene expression through an alternative mechanism. Daxx has been discovered
to act as a chaperone for the H3.3 histone variant. Recent studies demonstrate
that ATRX forms a chromatin remodeling complex with Daxx to deposit H3.3 at
both pericentromeric heterochromatin, and telomeres (Figure 1B) (Drané et al.,
2010; Goldberg et al., 2010; Lewis et al., 2010; Wong et al., 2010). It was
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determined that when ATRX is lost, H3.3 is no longer deposited in nucleosomes
at pericentromeric heterochromatin and telomeres, leading to decreased levels of
pericentromeric transcripts, and increased levels of telomeric transcripts in
embryonic stem cells (Wong et al., 2010).
In addition to influencing gene expression and the epigenetic environment of
chromatin, ATRX has also been implicated in the regulation of mitosis. Initially, it
was determined that ATRX becomes hyperphosphorylated during mitosis
suggesting that it may be required for proper cell-division (Bérubé et al., 2000). In
vitro studies have shown that human cells deficient for ATRX, display an irregular
assembly of chromosomes at the metaphase plate, disruption of spindle
morphology, and a delay in cell-cycle progression resulting in irregular nuclei
morphology (Ritchie et al., 2008). In addition, mice lacking ATRX exhibited an
increase in the abundance of micronuclei in the ventricular zone of the forebrain
coinciding with previous in vitro findings.
These studies show that ATRX is required for multiple cellular functions, and loss
of ATRX can lead to severe detriments during development.

1.1.3

ATR-X syndrome

ATR-X syndrome (OMIM#301040) is a neurodevelopmental disorder that is
characterized by a wide range of phenotypic aberrations such as severe
cognitive deficits, seizures, microcephaly, various developmental abnormalities,
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and alpha thalassaemia (a decrease of α-globin abundance in the blood)
(Gibbons et al., 1995; Gibbons and Higgs, 2000; Gibbons, 2006). ATR-X
syndrome patients have been shown to display intellectual disability associated
with a profound mental retardation (95% of patients), genital abnormalities (80%),
skeletal abnormalities (90%), microcephaly (reduction in brain size) (75%),
seizures (30%), HbH inclusions (87%), and characteristic facial features (94%)
(Gibbons, 2006). Recent magnetic resonance imaging (MRI) studies have also
revealed that ATR-X syndrome patients display varying degrees of white matter
abnormalities, and delayed myelination (Wada et al., 2013).
ATR-X syndrome results from hypomorphic mutations within the ATRX gene,
resulting in protein dysfunction. The majority of mutations in the non-truncated
form of ATRX resulting in ATR-X syndrome, occur in the ADD DNA binding
domain (49% of cases), and the SWI/SNF2 ATPase chromatin remodeling
domain (30% of cases) (Gibbons et al., 2008). It has been postulated that
mutations within the remaining domains of the ATRX protein act as neutral
polymorphisms rather than lethal mutations (Mitson et al., 2011).
Mutations within the Snf2 ATPase domain were found to result in defective DNA
translocase and ATPase activity, as well as abnormal localization of ATRX to
promyelocytic leukaemia nuclear bodies (PML-NB) (Bérubé et al., 2008; Mitson
et al., 2011). Furthermore, missense mutations within the ADD domain result in a
significant decrease of DNA binding ability, and abnormal targeting to
pericentromeric heterochromatin (Argentaro et al., 2007). These findings indicate
that ATRX has a subnuclear function in maintaining proper brain development.

9

ATR-X syndrome is an extremely rare disorder, as approximately only 200
people (prevalence of <1-9/1,000,000) have been diagnosed worldwide
(Gibbons, 2006). However, it is estimated that the prevalence of ATR-X may
actually be closer to 1/30-40,000 as some patients have yet to be diagnosed
(Wada et al., 2013). ATR-X syndrome primarily affects males, as the ATRX gene
is located on the X-chromosome. Females carrying a mutated ATRX allele are
phenotyically normal as their cells undergo the phenomenon of non-random Xinactivation (Gibbons et al., 1992).
In addition to ATR-X syndrome, mutations within the ATRX gene have been
implicated in several other neurological disorders such as Juberg-Mar-sidi, Xlinked mental retardation with spastic paraplegia, Carpenter-Waziri, HolmesGang, Smith-Fineman-Myers, and Chudley-Lowry syndromes (Villard et al.,
1996; Abidi et al., 1999; Lossi et al., 1999; Stevenson et al., 2000; Villard et al.,
2000; Abidi et al., 2005)
ATRX has been implicated to be crucial for proper brain development, as
mutations within the ATRX gene result in a severe neurological disorder.
Therefore, it is imperative to study the ATRX protein to further our knowledge of
its subcellular function in brain development. By increasing our knowledge of the
ATRX protein, therapies can be devised to combat the neurological disorders
that stem from mutations within ATRX.
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1.1.4

Phenotypic abnormalities associated with ATRX
loss

As

mentioned

above,

ATR-X

syndrome

patients

display

a

series

of

developmental abnormalities, and it has been found that a number of these
abnormalities are also illustrated in mice deficient for ATRX. To study the
phenotypic changes in mice when ATRX is lost, Bérubé and colleagues
developed a mouse model that lacks Atrx expression specifically from the
forebrain beginning at embryonic day 8.5 (E8.5) (Bérubé et al., 2005).
Analysis of the prenatal mouse brain revealed that loss of ATRX results in a
reduction of overall brain size. This was found to be due to hypocellularity in both
the cerebral cortex and hippocampus that results from a dramatic increase in the
number of apoptotic cells (Bérubé et al., 2005). It was further determined that the
increase in apoptosis is not the only mechanism that contributes to a reduction in
brain size when ATRX is lost. Seah and colleagues utilized a mouse model
where both ATRX and the tumour suppressing factor p53 were absent (Seah et
al., 2008). Analysis of newborn mice lacking both ATRX and p53 expression,
displayed decreased brain size compared to littermate matched controls (Seah et
al., 2008), suggesting that ATRX functions within multiple mechanisms to
regulate proper brain development.
It has recently been reported that ATRX is also required in neural progenitor cell
(NPC) development and maintenance. Loss of ATRX from the mouse forebrain
was found to negatively affect cortical layer development in the cerebral cortex.
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Layer VI of the cortex was found to be inflated, whereas layers II-IV were found
to be reduced with the loss of ATRX (Ritchie et al., 2014). This abnormality in
cortical development was determined to be the result of premature cell-cycle exit
of NPCs as well as a depletion of apical progenitor cells during the initial stages
of neurogenesis (Ritchie et al., 2014). Taken together, these results highlight the
importance for proper ATRX function during the early stages of brain
development.
In addition to brain development defects, mice lacking ATRX also display
additional developmental abnormalities. Mice deficient for Atrx were found to
have a shortened lifespan (approximately 23 days on average), and it was
resolved that this mortality rate was not due to starvation (Watson et al., 2013).
Total body weight, and body length were significantly reduced in ATRX-null mice
when compared to their control counterparts. In addition, these mice also
displayed kyphosis (abnormal curvature of the spine), decreased bone mineral
density, loss of trabecular bone, and decreased cortical bone thickness (Watson
et al., 2013). Watson and colleagues determined that Atrx-deficient mice also
display a number of endocrine defects. It was determined that levels of the
insulin-like growth factor 1 (IGF-1) as well as circulating thyroxine (T4) levels
were significantly reduced in ATRX-null mice (Watson et al., 2013).
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1.2 Myelination
1.2.1

The myelin sheath

The myelin sheath is a specialized and modified plasma membrane that
encompasses axons of neurons in higher-order vertebrates. Emerging
approximately 400 million years ago in cartilaginous fish, the myelin sheath
allows for increased propagation of action potentials along nerve fibres, as well
as providing trophic support and protection to the axonal cell body (Baumann and
Pham-Dinh, 2001; Zalc et al., 2008). It has been said that myelination of neurons
accelerates nerve conduction 20-100 fold then compared to unmyelinated fibres
(Nave and Werner, 2014). Myelinated segments are separated by unmyelinated
openings known as the nodes of Ranvier; the location on the axonal membrane
where sodium/potassium ion (Na+/K+) exchange occurs. When an electrical
current is generated, it travels along the axonal membrane where it maintains its
excitatory state due to depolarization at the nodes of Ranvier. Depolarization at
these nodes, gives the impression that the electrical signal is jumping from node
to node, a sensation known as saltatory conduction. Limiting the abundance of
sodium channels as well as extending the distance between channels,
significantly reduces the amount of ATP required, thus saving the amount of
energy needed to propagate action potentials (Wang et al., 2008). Interestingly,
the thickness of the myelin sheath is directly proportional to the thickness of the
axon; therefore the thicker the axon, the thicker the myelin sheath needs to be to
allow for proper firing of action potentials (Baumann and Pham-Dinh, 2001).
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1.2.2

Oligodendrocyte development

In the central nervous system (CNS) the myelin sheath is generated by
oligodendrocytes (OLs), whereas the myelin sheath in the peripheral nervous
system (PNS) is generated by Schwann cells.
OLs are a subpopulation of glial cell that are responsible for myelinating axons in
the CNS. Mature myelinating OLs arise due to the differentiation of OL precursor
cells (OPCs) (Figure 2). Multipotential NPCs are directed to become OPCs
through several extrinsic factors. Ventrally derived sonic hedgehog (SHH) was
found to influence NPC specification by binding to the Notch-1 receptor on the
NPC surface thereby activating the co-receptor Smoothened, which then induces
oligodendrocyte transcription factor 2 (Olig2) and NK6 homeobox protein (Nkx6)
expression (Pringle et al., 1996; Orentas et al., 1999). Induction of these two
factors leads to the first appearance of OPCs in the telencephalon.
In addition to SHH signaling, it has been reported that fibroblast growth factor 2
(FGF2) signaling has an independent role in the transition of NPCs into OPCs
(Chandran et al., 2003; Naruse et al., 2006). It was determined that FGF2
stimulates either FGF receptor 1 or 2 (FGFR1 or FGFR2), which then activates
the extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2) (Chandran et
al., 2003; Furusho et al., 2011). Phosphorylation of ERK1 and ERK2
subsequently blocks SMAD signaling, causing the activation of the OL-lineage
marker Olig2 (Bilican et al., 2008).
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Figure 2. The oligodendrocyte development pathway
Oligodendrcoyte precursor cells (OPCs) arise in the subventricular zone of the
mouse brain from the medial ganglionic eminence, lateral ganglionic eminence,
and the cerebral cortex beginning at E11.5, E15, and at birth respectively
(Kessaris et al., 2006). OPCs then migrate to their targeted axon where they then
undergo a wave of differentiation into postmitotic immature oligodendrocytes,
which then mature into myelinating oligodendrocytes (Rowitch, 2004).
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OPCs initially arise in the subventricular zone of the cortex, where they undergo
a wave of proliferation, followed by subsequent migration to their targeted axon
(Kessaris et al., 2006; Richardson et al., 2006). OPCs are identified by the
expression of platelet derived growth factor, alpha (PDGFRα), and NG2, a
protein encoded by chondroitin sulfate proteoglycan 4 (Cspg4). Both the cellsurface receptor PDGFRα, and the proteoglycan NG2 are important in
maintaining the proliferative state of OPCs (Nishiyama et al., 1996; Soriano,
1997). OPC proliferation requires PDGFRα expression, as it is the receptor for
the potent PDGFA mitogen (Soriano, 1997). In addition to PDGFA, it has been
determined that IGF-1 may also be a factor associated with OPC proliferation.
IGF-1 regulates OPC proliferation by activating the PI3K/Akt pathway via the
IGF-1 receptor (IGF-1R). Activation of the PI3K/Akt pathway promotes the
expression and survival of cyclin-D1, a known factor important in cell-cycle
progression (Pang et al., 2007; Zeger et al., 2007; Bibollet-Bahena and Almazan,
2009; Romanelli et al., 2009).
Migration of OPCs to their targeted axons relies on various mechanisms
including motogenic factors, and cell adhesion molecules. PDGFA and FGF-2
are two of the most important motogenic factors that influence OPC migration.
PDGFA affects OPC migration by activating the phosphorylated version of the
Wasp Veprolin-homologous protein 2 (WAVE2) family of migratory proteins
through the Fyn, and cyclin-dependent kinase 5 (Cdk5) pathways (Miyamoto et
al., 2008). On the other hand, FGF-2 independently promotes migration through
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its recognition and stimulation of FGFR1 on OPCs (Bansal et al., 1996;
Osterhout et al., 1997; Bribián et al., 2006).
Cell adhesion molecules also play a vital role in promoting migration of OPCs to
their targeted axon. As OPCs migrate throughout the extracellular matrix (ECM),
they come into contact with various molecules that further aid their movement. It
has been shown that molecules such as laminin, fibronectin, merosin, tenascinC, and anosmin-1 are all pro-migratory factors that assist OPC progression
throughout the forebrain during development (reviewed in Mitew et al., 2014).
OPCs require several mechanisms acting in unison to properly migrate
throughout the forebrain and through the ECM to reach their targeted axon. Upon
reaching their final destination, OPCs undergo terminal differentiation into
postmitotic immature premyelinating OLs (iOLs) (Rowitch, 2004).
Differentiation of OPCs into iOLs requires several intrinsic and extrinsic factors
that act to promote differentiation. It has been shown that OL-specific factors
such as achaete-scute homolog 1 (Ascl1) and NK2 homeobox protein 2 (Nkx2.2)
are critical for OPC differentiation, as loss of these factors results in a substantial
decrease in the number of differentiated iOLs present in the forebrain (Qi et al.,
2001; Sugimori et al., 2008). Furthermore, OLIG2 has been found to activate
genes that are required for OPC differentiation. OLIG2 regulates this process by
promoting binding of the BRM/SWI2-related gene 1 (BRG1) chromatin
remodeling protein to the regulatory regions of genes known to be required for
OPC differentiation including SRY-box 10 (Sox10), and zinc finger homebox 1b
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(Zfhx1b) (Yu et al., 2013). Several additional regulators that positively influence
OPC differentiation have been discovered including triiodothyronine (T3). Studies
have shown that the abundance of postmitotic iOLs is severely diminished when
T3 levels are reduced, resulting in severe hypomyelination (Mitew et al., 2014).
Although the influence of T3 in the promotion of OPC differentiation is well
known, the exact mechanisms influencing differentiation remain unclear.
There are several factors that negatively influence differentiation of OPCs as
well. A long known inhibitor of OPC differentiation is the leucine-rich
immunoglobulin domain-containing, 1 (LINGO-1) (Mi et al., 2004; 2005). LINGO1 negatively regulates OPC differentiation through two independent mechanisms.
First, LINGO-1 negatively regulates the Fyn kinase signaling pathway, which
consequently upregulates RhoA signaling which has been found to reduce
differentiation capacity (Mi et al., 2005). In addition, LINGO-1 also binds to OPCspecific LINGO-1, which has been shown to negatively regulate OPC
differentiation (Jepson et al., 2012). An additional well-known inhibitor of OPC
differentiation is the G-protein coupled receptor 17 (GPCR17). It has been shown
that overexpression of GPCR17 significantly reduces the differentiation capacity
of OPCs by increasing the expression of inhibitor of DNA-binding protein 2 and 4
(ID2 and ID4) proteins (Chen et al., 2009); two known factors in the promotion of
cell-cycle progression (Iavarone et al., 1994). Conversely, depletion of GPCR17
has been shown to promote premature differentiation, thus displaying the
relevance of GPCR17 function during OL-development (Chen et al., 2009).
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Myelination of neurons requires maturation of immature premyelinating OLs into
myelinating OLs. Initially, OLs extend membranous processes that contact
axonal cell bodies resulting in the initiation of myelination. These membranous
processes, also known as filopodia, are abundant in microfilament fibres. Several
axonal signaling molecules such as laminin-α2 promote the extension of these
processes (Morissette and Carbonetto, 1995; Colognato et al., 2002). Binding of
laminin-α2 to the OL-specific β-1 receptor promotes the dephosphorylation of the
Fyn tyrosine kinase leading to the activation of integrin-linked kinase (ILK),
particularly interesting new cysteine-histidine-rich protein (PINCH), and α-parvin.
Activation of these factors allows for the initiation of actin polymerization and
consequently, filopodia extension (Hu et al., 2009).
Inhibitory factors of myelination initiation have also been well studied.
Polysialylated neural cell adhesion molecule (PSA-NCAM), as well as Jagged-1
signaling through the Notch-1 receptor are well known factors that inhibit OL
process extension and contact to the axonal cell body (Wang et al., 1998;
Charles et al., 2000). In addition, LINGO-1 binding to the Nogo receptor on OLs
also negatively regulates myelination as it reduces the extension abilities of OL
filopodia (Mi et al., 2004; 2005).
After the initial contact of the cytoplasmic membranous processes to the
unmyelinated axon, the generation of the growing myelin sheath requires several
myelin-specific factors that act to maintain sheath stability, compaction, and
thickness. The regulatory mechanisms of myelin-specific gene expression have
yet to be completely identified; however, there are several transcription factors
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that have been found to be important for myelin-specific gene expression and
consequently, myelin sheath formation and maintenance.
One such factor that has been found to regulate myelin-specific gene expression
is myelin regulatory factor (MRF). MRF was first identified as a transcriptional
regulator of myelin-specific gene expression by Emery and colleagues (Emery et
al., 2009). MRF is a nuclear protein that contains a DNA binding domain
homologous to the Ndt80 yeast transcription factor, and is expressed exclusively
in postmitotic OLs (Cahoy et al., 2008; Emery et al., 2009). Emery and
colleagues determined that loss of MRF from OLs results in a dramatic decrease
in the expression of several myelin-specific proteins including myelin basic
protein (MBP), proteolipid protein (PLP), myelin-associated glycoprotein (MAG),
and myelin oligodendrocyte glycoprotein (MOG) (Emery et al., 2009). On the
other hand, induced expression of MRF in cultured OPCs stimulated the
premature expression of these proteins leading to premature myelin formation,
suggesting that MRF is directly regulating the expression of these genes (Emery
et al., 2009). In addition, MRF has been noted to be important for myelin sheath
maintenance, as ablation of MRF from myelinating OLs in 8-week-old mice
correlated with severe demyelination (Koenning et al., 2012). Interestingly, Mrf
expression was found to be directly regulated by the OL-specific factor SOX10 as
it binds to an intronic enhancer in the Mrf transcript (Hornig et al., 2013). MRF
has been found to be a potential master regulator of myelin-specific gene
expression; however, the exact mechanism of MRF has yet to be elucidated.
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In addition to MRF, a transcription factor found to be important in myelin-specific
gene expression is the putative transcription factor zinc finger protein 191
(ZFP191). It was determined that loss of ZFP191 results in a severe
hypomyelination phenotype in the postnatal day 14 (P14) mouse brain (Howng et
al., 2010). Transmission electron microscopy analysis of extracted spinal cord,
revealed that ZFP191 mutants displayed a global reduction of myelin correlating
with the significant reduction in myelin-specific protein expression (Howng et al.,
2010). Interestingly, it was determined that loss of ZFP191 did not affect OPC
production, proliferation, or differentiation into premyelinating OLs suggesting
that it is only required for iOL maturation and myelination initiation. Furthermore,
Howng and colleagues determined that ZFP191 also acts in an OL cellautonomous manner to regulate myelin-specific genes, similar to MRF (Howng et
al., 2010). It is strongly suggested that additional regulatory factors are required
in the molecular network that controls the expression of myelinating factors;
however, the majority of these factors have yet to be identified.

1.2.3

Composition of the myelin sheath

The myelin sheath is a complex, lipid-rich membrane that is assembled and
maintained by the intricate interaction of proteins and lipids. It has been
established that in the CNS, 15-30% of the dry weight of myelin consists of
myelin-specific proteins, and 70-85% consists of lipids (Baumann and Pham-
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Dinh, 2001; Quarles, 2005). Interestingly, this proportion of protein to lipids is
unique and specific to myelin.

1.2.3.1

Myelin-specific proteins

Two of the most prominent and vital proteins present within the myelin sheath are
MBP and PLP. The MBP protein consists of several different isoforms that are
the result of an alternative splicing event of the Mbp gene. Mbp is located on
chromosome 18 in both the mouse and human genome, consisting of seven
exons and spanning 32 kb and 45 kb respectively (Roach et al., 1983; Saxe et
al., 1985; Sparkes et al., 1987; Gogate et al., 1994). Two of the most prevalent
isoforms (approximately 95%) of MBP are the 14 and 18.5 kDa isoforms in mice,
and the 17.2 and 18.5 kDa isoforms in humans (Staugaitis et al., 1990).
MBP is a crucial factor in myelination as it is required for the formation,
stabilization, and maintenance of the multilameller structure of myelin
(Campagnoni and Skoff, 2001). MBP is involved in the tight compaction of the
myelin sheath as it found between, and pulls together two negatively charged
surfaces of the lipid membrane forming the major dense line of the myelin sheath
(Harauz et al., 2009; Min et al., 2009; Aggarwal et al., 2013). It has been found
that mice lacking MBP display significant myelin abnormalities. Mice lacking MBP
display severe dysfunction in the compaction of the myelin sheath, demonstrating
the necessity of MBP in myelin sheath stability and functionality (Privat et al.,
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1979; Roach et al., 1985). MBP is essential in proper brain development as it is a
limiting factor in CNS myelination.
In addition to MBP, PLP is also a known factor that is vital to the compaction and
stabilization of the myelin sheath. PLP is a 20 kDa protein that is encoded by
Plp1, a small (15 kb) gene located on the X-chromosome. PLP is a tetraspan
protein that contains four hydrophobic α-helices that span the lipid bilayer
(Weimbs and Stoffel, 1992). Interestingly, the N-terminus and C-terminus of PLP
are found on the cytoplasmic sides of the lipid bilayer, which acts to stabilize the
myelin sheath (Weimbs and Stoffel, 1992; Boison et al., 1995). It has been
shown that mice lacking PLP, display severe axonal damage due to severe
hypomyelination (Quarles and Macklin, 2005). PLP is not only an important factor
for the stabilization and maintenance of the myelin sheath, but it is also crucial for
providing protection to the axonal cell body. Together, MBP and PLP constitute
80% of the total proteins in myelin sheath composition (Baumann and PhamDinh, 2001). MBP and PLP are the two most prevalent proteins found in the
myelin sheath; however there are additional proteins that are vital for proper
myelination in the CNS, such as MAG, and MOG.
MAG is a cell-adhesion glycoprotein that is located on the periaxonal glial
membrane of the myelin sheath. Biochemical analysis of the MAG protein shows
it has high homology to neural cell-adhesion molecule (NCAM) (Lai et al., 1987).
Due to its location as well as its homology to NCAM, it has been postulated that
MAG may be an important factor in myelin sheath initiation. This theory is
strengthened as loss of MAG has been shown to disrupt glial-axonal contact in
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mice (Li et al., 1998). In addition, in vivo mouse studies have shown that CNS
myelination is delayed in the absence of MAG (Montag et al., 1994; Bartsch et
al., 1997). These studies strongly support the notion that MAG is important in
myelin sheath development. Although the exact function of MAG is still being
debated, it has been noted to also be important for OL differentiation, as well as
myelin sheath maintenance and survival (Quarles, 2007).
MOG is a transmembrane glycoprotein that is found on the outermost surface of
the myelin sheath (Pham-Dinh et al., 1993). MOG has been found to be involved
in the completion and maintenance of the myelin sheath, as well as being
important for cell-cell communication and mediation of homophilic cell-cell
adhesion (Roth et al., 1995; Baumann and Pham-Dinh, 2001; Clements et al.,
2003).

1.2.3.2

Lipid content of the myelin sheath

In addition to myelin-specific proteins, the CNS myelin sheath is composed of a
high content of lipids. It has been found that the myelin sheath is comprised of
cholesterol, phospholipids, galactolipids, and plasmologens at a ratio of 2:2:1:1
respectively (Norton and Poduslo, 1973). Cholesterol is a major constituent of the
myelin sheath as it constitutes approximately 26% of the dry weight of myelin
(Norton and Cammer, 1984). Previous studies have found that cholesterol in
CNS myelin is synthesized locally and is independent of cholesterol levels in
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circulation (Jurevics and Morell, 1995). The myelin sheath in the CNS displays an
unusually high content of cholesterol, as it is 2-fold more abundant in CNS myelin
compared to any other plasma membrane. The high level of cholesterol affects
myelin

compartmentalization

and

intracellular

trafficking

by

influencing

membrane thickness and fluidity (Nave and Werner, 2014). Previous in vivo
studies have shown that, OLs that cannot synthesize cholesterol display a delay
in myelin production, signifying that cholesterol biosynthesis is a rate-limiting step
in CNS myelination (Saher et al., 2005).

1.2.4
There

Pathologies related to myelin sheath dysfunction
are

several

known

neurodegenerative,

neurodevelopmental,

and

neuropsychological disorders associated with defects in myelination. The most
familiar disorder associated with myelin sheath dysfunction is multiple sclerosis
(MS). MS is a neurodegenerative disorder that is the result of demyelination and
axonal degeneration. The mechanistic origin of MS remains controversial, as
both environmental factors and viral infection have been determined to promote
disease onset (Ascherio and Munger, 2007; Compston and Coles, 2008).
Although the origin of MS remains debatable, the disease phenotype is
characterized by the formation of sclerotic plaques. Sclerotic plaque formation
results in severe inflammation causing demyelination, OL death, astrocytosis,
and subsequent axonal degeneration (reviewed in Compston and Coles, 2008).
Although, the myelin sheath is able to partially regenerate, it is unable to maintain
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its overall integrity, thus leading to permanent demyelination and axonal
degeneration. Degradation of axons due to demyelination in MS patients have
been found to lead to severe cognitive defects, tremors, reduced visual acuity,
spasticity, and over weakness of the body eventually leading to premature death
(reviewed in Compston and Coles, 2008). To date, therapies addressing MS
focus on targeting the immune system to suppress the advancement of
demyelination of neurons rather than focusing on the mechanisms to induce
remyelination (Nave and Werner, 2014). In addition to MS, myelination
dysfunction has been characterized in several leukodystrophies, as well as
schizophrenia. Leukodystrophies are a family of disorders that arise due to
specific genetic mutations resulting in demyelination of CNS axons.
Pelizaeus-Merzbacher disease (PMD) is a member of the leukodystrophy family
that results from mutations within the Plp1 gene causing abnormal levels of the
PLP protein (OMIM#312080). Resulting mutations in Plp1 cause severe
demyelination in multiple areas of the brain including the cerebral cortex and
cerebellum (Seitelberger, 1995). Boys affected with PMD display a severe
deterioration in intellectual function, impaired movement, ataxia, and spasticity
(Inoue, 2005). Current therapies for PMD patients target treatment for seizures
and spasticity, in addition with physical therapy (Xia and Wang, 2013); however,
therapies focusing on targeting the molecular mechanisms of PMD have yet to
manifest.
An additional and rare leukodystrophy that is well known is Krabbe disease (KD).
KD is the result of mutations in the gene that codes for the lysosomal enzyme
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galactocerebrosidase (GALC) (OMIM#245200). Abnormal GALC levels results in
a failure to breakdown galactosylceramide and psychosine leading to the
degeneration of the myelin sheath (Suzuki, 2003a; 2003b). Current treatments
include introduction of chemical chaperones to reactivate defective enzymes
(Berardi et al., 2014); however, no cure has been found.
Recent studies have shown that myelination defects may also be a contributing
factor to the disease pathology in individuals with schizophrenia. It was
determined that several schizophrenic patients displayed a disruption in both
oligodendrocytes and myelination (reviewed in Haroutunian et al., 2014).
Furthermore, expression of genes involved in oligodendrocyte development and
myelination was altered in extracted tissue from deceased schizophrenic
patients. Genetic alterations resulting in myelination defects, coincide with
several neurological and behavioural symptoms seen in individuals with
schizophrenia (reviewed in Haroutunian et al., 2014). Experimental procedures
performed on animal models of schizophrenia, revealed that moderate changes
in OL-associated genes resulted in behaviors similar to that seen in human
schizophrenic patients (Gregg et al., 2009), suggesting that abnormal OL
development and myelination may be a cause, or result of schizophrenia.
Abnormal OL development and myelination is associated with several
neurodevelopmental, neurodegenerative, and neuropsychological disorders;
however, the exact mechanisms involved have yet to be fully elucidated, thus
restricting the identification of new, improved, and less invasive therapies for
these disorders.
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1.3 Hypothesis and thesis objectives
It has been recently discovered that in addition to the severe developmental
abnormalities, ATR-X syndrome patients also display moderate to severe
myelination defects that correlate with diminished cognition (Wada et al., 2013).
As ATRX has been implicated in the regulation of the epigenetic environment of
heterochromatin, and gene expression;
I hypothesize that the ATRX chromatin remodeling protein is required for
proper myelin formation in the CNS by regulating the expression of myelinspecific genes.
To test this hypothesis, I set out to: (1) determine if myelination is disrupted in the
absence of ATRX from the mouse forebrain, (2) determine at what stage in the
oligodendrocyte development pathway ATRX is required to initiate myelination,
and (3) determine if ATRX has an oligodendrocyte-specific mechanism in CNS
myelination.
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Figure 3. Hypothetical mechanism of ATRX in myelination of neurons
within the CNS
I hypothesize that ATRX directly regulates the expression of myelin-specific
genes within oligodendrocytes that code for proteins that are required for
oligodendrocyte process extension, myelin sheath initiation, as well as myelin
sheath compaction and stabilization
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2

Materials and Methods

2.1 Animal husbandry, tissue harvesting, and genotyping
All mice were housed in clear cages at 22±1°C and subjected to a 12/12 hour
light/dark cycle. All mice were fed a standard diet (Harlan Laboratories) and a
water bottle was placed in each cage so water was available ad libitum. All mice
were housed, bred, euthanized, and tissues harvested in a facility designed to
maintain mice.
In this study, multiple mouse lines were used. Female mice harbouring loxP sites
flanking exon 18 of the Atrx gene (Atrxf/f) were kindly provided by Dr. Douglas
Higgs (Weatherall Institute of Molecular Medicine, John Radcliffe Hospital,
Oxford, United Kingdom). Deletion of exon 18 from the Atrx gene results in a
truncated and unstable mRNA transcript, thus becoming vulnerable to
degradation and ultimately eradicating the presence of the ATRX protein.
Recombination of exon 18 from the Atrx gene mirrors the effect of an ATRX-null
mutation (Bérubé et al., 2005).
Heterozygous female mice containing loxP sites flanking exon 18 of the Atrx
gene (Atrxf/wt) were crossed with male mice that have Cre recombinase inserted
into the forkhead box G1 (FoxG1) locus, thus allowing for the complete loss of
Atrx expression specifically from the forebrain beginning at E8.5. Male progeny
resulting from this cross will be used to assess the role of
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Figure 4. Schematic of mice harbouring loxP sites used for Cre-loxP
recombination.
The top schematic represents the wild-type allele with normal Atrx expression.
The second schematic represents the allele that has loxP sites flanking exon 18
of the Atrx gene. The third schematic represents the result of recombination
using Cre-loxP technology resulting in complete loss of exon 18 of the Atrx gene.
The white bars represent exons of the Atrx gene, and the black triangles
represent loxP sites located in the Atrx gene.
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ATRX in the mouse forebrain, as female mice heterozygous for Atrx expression
are phenotypically normal. Male mice that have Atrx knocked out from the
forebrain (AtrxFoxG1Cre) were used as experimental mice, and male mice that
express Cre recombinase but do not contain loxP sites flanking exon 18 of the
Atrx gene were used as control mice.
An additional mouse line was utilized to determine if ATRX has an OL-specific
role in myelination development. Male mice that have Cre recombinase inserted
into the 2’, 3’-cyclic-nucleotide 3’-phosphodiesterase (Cnp) locus were generated
by Dr. Klaus-Armin Nave (Max Planck Institute for Experimental Medicine,
Göttingen, Germany) (Lappe-Siefke et al., 2003), and generously provided by Dr.
Brian Popko (University of Chicago, Chicago, Illinois, U.S.A) with the permission
from Dr. Nave. These male mice were mated with heterozygous female mice
containing loxP sites flanking exon 18 of the Atrx gene (Atrxf/wt). The resulting
male progeny (AtrxCnpCre) from this cross lack ATRX specifically from the OL celllineage beginning at E11.5 (Lappe-Siefke et al., 2003).
To determine the genotypes of our mice, genomic DNA was extracted from tail
clips/ear notches from each mouse by incubating these samples in a solution of
100µL of DirectPCR and 5µL of proteinase K (ThermoScientific) for 12 hours at
55°C. PCR was then performed using primers designed to amplify the Atrx, Cre,
and Sry genes under the following conditions: Step 1. Initial denaturation - 95°C
for 3 minutes, Step 2. Denaturation - 95°C for 30 seconds, Step 3. Annealing 55°C for 30 seconds, Step 4. Elongation - 72°C for 1:30 minutes (Note: Steps 2-4
were performed for 35 cycles), followed by Step 5. 72°C for 5 minutes. Primer
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designs can be located in Table 1. Following PCR amplification, each sample
was then ran on a 1.5% agarose gel for separation, and then imaged using the
BioRad Universal Imaging hood (BioRad).
The mice chosen for either quantitative real-time PCR (qRT-PCR) or western blot
analysis were euthanized using carbon dioxide (CO2) inhalation followed by
cervical dislocation. The mice chosen for immunohistological analyses were
euthanized using CO2 inhalation, and fixed by cardiac perfusion. Cardiac
perfusion was performed by first injecting 10mL of 1x phosphate buffered saline
(PBS), followed by injection of a 30mL solution of 4% paraformaldehyde (PFA).
Following cardiac perfusion, whole mouse brains were harvested and placed in a
15mL conical tube containing 10mL of 4% PFA. Post-fixation of whole mouse
brains was carried out for 12 hours at 4°C. Once post-fixation was complete,
whole mouse brains were then transferred to a solution of 30% sucrose diluted in
1xPBS for cryoprotection. Following cryoprotection, whole mouse brains were
embedded in OCT (optical cutting temperature) media and flash frozen using
liquid nitrogen. Brain tissues were then stored in a -80°C freezer until further use.

2.2 Microarray analysis
To assess gene expression changes between AtrxFoxG1Cre and control mouse
brains at both postnatal day 0.5 (P0.5) and P17, a gene expression microarray
was performed by a member of the laboratory, Dr. Michael Levy (unpublished).
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RNA was extracted from the forebrain of three pairs of P0.5 AtrxFoxG1Cre and
control mice, as well as three pairs of P17 AtrxFoxG1Cre and control mice using the
RNeasy Mini Kit (QIAGEN). Total RNA was then sent to the London Regional
Genomics Centre (LRGC) for microarray analysis. First, cDNA was synthesized
using SuperScriptII (Invitrogen) and oligo (dT24) primers. Biotin-labeled cRNA
was then prepared by cDNA in vitro transcription using the BioArray High-Yield
RNA Transcript Labeling kit (Enzo Biochem) to incorporate biotinylated UTP and
CTP. Biotinylated labeled cRNA was then hybridized to an Affymetrix Mouse
Genome 430 2.0 array chip for 16 hours at 45°C and 60rpm. One microarray chip
per mouse was used. GeneChips were stained with streptavidin-phycoerythrin
(SAPE), followed by an antibody solution and a second SAPE solution, with all
liquid handling performed by a GeneChip Fluidics Station 450. GeneChips were
scanned with the Affymetrix GeneChip Scanner 3000 7G (Affymetrix) where the
GCOS1.4 program was used to generate probe level (.CEL file) data.
Probe level data was then transferred into the Partek Genomic Suite program
(Partek), and the RMA algorithm (Irizarry et al., 2003) was used to summarize
each probe signal, and output the data as probe intensity levels. Summarizing
the probe signal utilizing the RMA algorithm consists of, binning the data to
reduce the variation within each group, background correction, and normalization
of the data from each array chip to each other. Once the probe intensity levels
have been determined, a one-way ANOVA was used to calculate the p-values for
each probe set. Furthermore, gene expression fold-changes in AtrxFoxG1Cre
mouse brains compared to control mouse brains were calculated using the
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Fisher’s least significant difference model (Tamhane and Dunlop, 2000). Gene
ontology (GO) analysis of specific gene subsets was performed using the
Fisher’s exact test (Rhee et al., 2008) in the Partek Genomic Suite program
(Partek). Heat maps of selected gene targets were generated using respective
probe intensity levels from both AtrxFoxG1Cre and control mice.

2.3 Quantitative real-time PCR
Total RNA was isolated from control and knockout mouse forebrains using the
RNeasy Mini Kit (QIAGEN). Quantity and quality of isolated RNA was then
measured using the Nanodrop1000 (Thermo Scientific). RNA was then reverse
transcribed into cDNA using standard PCR settings (65°C for 10 minutes,
followed by 30°C for 10 minutes, then 42°C for 45 minutes). Confirmation of
reverse transcription was carried out by PCR using primers designed to the
internal control, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) (Table 1).
PCR amplification was performed using standard settings. PCR samples were
then loaded onto a 1.5% agarose gel and ran at 95V for 22 minutes, and then
imaged.
qRT-PCR was carried out to study gene expression changes between
AtrxFoxG1Cre and control mouse forebrains. First, the online Ensembl genome
browser 84 database (http://www.ensembl.org/index.html) was used to identify
optimal gene
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Table 1. Primer sequences for PCR and qRT-PCR
Gene

Forward primer (5’ to 3’)

Reverse primer (5’ to 3’)

Mbp

ATCCAAGTACCTGGCCACAG

CAGGGAGCCATAATGGGTAG

Mog

AAATGGCAAGGACCAAGATG

AAGTGCGATGAGAGTCAGCA

Mag

GCCTGTACCTGGATCTGGAG

ATGACCGTGGCTAGGATCTG

Plp1

GGCCACTGGATTGTGTTTCT

GTGGTGTAGAAGCCCTCAGC

Mobp

GAGGAGGACTGGATCTGCTG

AGTCCTTGAAGGGGACCTTG

Cnp

GCTGGTTCCTGACCAAAAAG

CACCTGGAGGTCTCTTTCCA

Pdgfrα

ACCTCCCACCAGGTCTTTCT

GCCAGCTCACTTCACTCTCC

Cspg4

TCCAGATCACTGGGCCTTAC

AGGCGTCTGTCTGTGTCTCA
18 R - TGAACCTGGGGACTTCTTTG

Atrx

AGAACCGTTAGTGCAGGTTCA

Cre

TGACCAGAGATCATCCTTAGCG

AATGCTTCTGTCCGTTTGCC

Sry

GCAGGTGGAAAAGCCTTACA

AAGCTTTGCTGGTTTTTGGA

Gapdh

CAACGACCCCTTCATTGACCT

ATCCACGACCGACACATTGG

NeoR - CCACCATGATATTCGGCAAG
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locations to design DNA primers for PCR amplification. Using the desired gene
locations, the online Primer3 tool (http://bioinfo.ut.ee/primer3-0.4.0/) was used to
design optimal DNA primers. Primer sequences for each gene can be found in
Table 1. qRT-PCR was carried out on 96-well PCR plates. Each well on the 96well plate contained a combined solution of cDNA, H2O, the desired primers, and
iQT,MSYBR® Green Mastermix (BioRad). qRT-PCR was carried out using a
Chromo-4 thermocycler (BioRad) under standard conditions [Step 1. Initial
denaturation - 95°C for 3 minutes, Step 2. Denaturation - 95°C for 10 seconds,
Step 3. Annealing - 55°C for 20 seconds, Step 4. Elongation - 72°C for 30
seconds (Note: Steps 2-4 were performed for 30-35 cycles), followed by Step 5.
Final elongation - 72°C for 5 minutes]. A final melting curve was constructed in
increments of 1°C per plate read. Opticon Monitor 3 sofware (BioRad) was used
to calculate Ct values for each sample. Ct values for each well were calculated
automatically after resolving the threshold placement on the amplification curve.
Ct values were then transferred into the GeneX (BioRad) program to analyze the
gene expression data. Expression of each gene was calculated from two
technical replicates and three biological replicates. Gene expression was
normalized to Gapdh, and an unpaired students t-test was then used to
determine if expression of each gene was significantly different (p<0.05) between
control and knockout mice.
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2.4 Protein isolation
Total protein was extracted from control and knockout mouse forebrains using
RIPA lysis buffer (150mM NaCl, 1% NP-40, 50mM Tris, pH 8.0, 0.5%
deoxycholic acid, 0.1% SDS, 0.2mM PMSF, 0.5mM NaF, 0.1mM Na3VO4, and 1
protease inhibitor cocktail tablet). 200µL of RIPA buffer was added to a 1.5mL
PCR tube containing one half of a mouse forebrain. Forebrain tissue was then
homogenized and put on ice for 20 minutes for cell lysis. Total cell extracts were
cleared by centrifugation at 10000rpm at 4°C for 20 minutes to pellet cellular
debris, and then the supernatant containing the soluble cellular fraction was
collected. Protein quantification was then measured by Bradford assay (Bradford,
1976). Bradford assay was carried out by first adding 10µL of each sample into a
96-well plate. 190µL of protein assay dye reagent concentrate (BioRad) was then
added to each well. 0.5µg/µL, 1µg/µL, 2 µg/µL, 4µg/µL, 6µg/µL, and 8µg/µL of
bovine serum albumin (BSA) was used a controls. The 96-well plate was then
loaded into the Wallac Victor2, 1420 multilabel counter machine (Perkin Elmer)
where the absorbance of each individual sample was recorded. Each sample
was performed in triplicate, and therefore the average absorbance was used to
calculate the protein concentration of each sample. An X-Y scatter plot was
constructed placing the control BSA concentration values on the Y-axis, and the
corresponding wavelength values on the X-axis. A line of best fit was then
calculated in excel to determine the equation of the line. The measured
wavelength of each sample was inputted into this equation to determine their
subsequent protein concentration.
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2.5 Western blot analysis
Western blots were carried out using polyacrylamide gels. Each polyacrylamide
gel consisted of a 4% stacking gel (780µL ddH2O, 130µL 30% Acrylamide-Bis
(Bio-Rad), 65µL 2M Tris (pH 6.8), 10µL 10% SDS, 8µL 10% APS, 2µL TEMED
for a 1mL solution) and a separating gel. In this study, both a 6% separating gel
(5.9mL ddH2O, 2mL 30% Acrylamide-Bis (Bio-Rad), 2mL 2M Tris (pH 8.8),
100µL 10% SDS, 30µL 10% APS, 20µL TEMED for a 10mL solution) and a 12%
separating gel (3.9mL ddH2O, 4mL 30% Acrylamide-Bis (Bio-Rad), 2mL 2M Tris
(pH 8.8), 100µL 10% SDS, 30µL 10% APS, 20µL TEMED for a 10mL solution)
were used depending on the size of the desired proteins. A total of 8µL of protein
ladder (Bio-Rad), and 50ug of protein was loaded into the corresponding wells.
SDS-PAGE gels were run at 90V for 30 minutes, followed by 130V for 2 hours, in
1x running buffer. Protein from the gels was then transferred onto a nitrocellulose
membrane (Pall Life Sciences) at 75V for 2 hours in 1x transfer buffer.
Nitrocellulose membranes were then placed into a small plastic dish and blocked
with 5% milk-TBST for 1 hour at room temperature. Following this incubation, the
desired primary antibody (Table 2) was then diluted in 5mL of 5% milk-TBST and
added to the dish containing the membrane, and then incubated overnight at
4°C. The next morning, membranes were place on a rocker where they then
underwent 4, 10-minute washes with 1x TBST at room temperature. The
corresponding secondary antibody (Table 3) was then diluted in 5mL of 5% milkTBST and added on top of the membrane, and then incubated for 1 hour at room
temperature. Membranes then underwent another 4, 10-minute washes with
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Table 2. Primary antibodies used for Western blot analysis and
immunofluorescence staining

Protein

Antibody Description

Dilution of
primary antibody

Dilution of
secondary
antibody

ATRX (D-5)

Anti-mouse, polyclonal (Santa Cruz)

WB – 1:500

WB – 1:4000

ATRX (H300)

Anti-rabbit, polyclonal (Santa Cruz)

IF – 1:100

IF – 1:800

IF – 1:200

IF – 1:800

MBP

Anti-rat, monoclonal (Abcam)
WB – 1:3000

WB – 1:4000

IF – 1:200

IF – 1:800

WB – 1:3000

WB – 1:3000

MOG

Anti-mouse, monoclonal (Millipore)

MAG

Anti-mouse, monoclonal (Abcam)

WB – 1:000

WB – 1:4000

CNPase

Anti-mouse, monoclonal (Covance)

WB – 1:3000

WB – 1:4000

IF – 1:200

IF – 1:800

PDGFRα

Anti-rabbit, polyclonal (Abcam)
WB – 1:200

WB – 1:4000

APC (CC-1)

Anti-mouse, monoclonal (Millipore)

IF – 1:100

IF – 1:800

OLIG1

Anti-mouse, monoclonal (Santa
Cruz)

IF – 1:100

IF – 1:800

OLIG2

Anti-goat, polyclonal (Santa Cruz)

IF – 1:100

IF – 1:800

Actin

Anti-rabbit, polyclonal (Sigma)

WB – 1:1000

WB – 1:4000

INCENP

Anti-rabbit, polyclonal (Sigma)

WB – 1:10000

WB – 1:10000
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Table 3. Secondary antibodies used for Western blot analysis and
immunofluorescence staining
Secondary antibody and description

Experimental procedure
used

Anti-rat IgG HRP (Santa Cruz)

Western blot

Anti-mouse IgG HRP (Santa Cruz)

Western blot

Anti-rabbit IgG HRP (Santa Cruz)

Western blot

Alexa Fluorophore, goat anti-rabbit IgG 594 nm (Life Technologies)

Immunofluorescence

Alexa Fluorophore, goat anti-rat IgG 488 nm (Life Technologies)

Immunofluorescence

Alexa Fluorophore, goat anti-mouse IgG 594 nm (Life Technologies)

Immunofluorescence

Alexa Fluorophore, goat anti-mouse IgG 594 nm (Life Technologies)

Immunofluorescence

Alexa Fluorophore, donkey anti-goat IgG 594 nm (Life Technologies)

Immunofluorescence

44

1xTBST at room temperature. ECL (enhanced chemilluminescence) was then
added to the membrane for approximately 1 minute. The membrane was then
exposed onto chemilluminescence film, and then developed with the Konica
Minolta SRV-101A film developer (Konica Minolta). Protein expression was
measured by calculating the integrated density of each protein band using
ImageJ software. Protein expression was normalized to the corresponding
loading control. INCENP was used as the loading control for proteins that were
detected using 6% polyacrylamide gels, and Actin was used as the loading
control for proteins that were detected using 12% polyacrylamide gels. Unpaired
students t-test was then used to determine if the expression of the protein was
significantly different (p<0.05) between control and knockout mice.

2.6 Immunofluorescence staining and cell counting
Embedded whole mouse brains were coronally sectioned (Figure 5) to a
thickness of 8µm using the Leica CM100 cryostat (Leica Biosystems) and placed
on glass microscope slides. Slides were then placed in a -80°C freezer until
further use. 1 hour prior to starting the immunofluorescence protocol, slides
containing the frozen brain cryosections were taken out of the freezer to allow for
thawing. Once the samples were completely thawed, slides were placed into a
1xPBS solution for 5 minutes to allow for sample rehydration. Slides were then
placed into a slide holder containing a pre-warmed solution of 10mM sodium
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Figure 5. Coronal section of the postnatal mouse brain
Analysis of the postnatal mouse brain was performed by assessing two areas of
the brain that are rich in white matter and are important for proper cognitive
function; the corpus callosum and the cerebral cortex (outlined in red boxes).
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acetate for antigen retrieval.

Antigen

retrieval

was carried out by slightly

heating slides in a microwave for 10 minutes. Slides were then taken out, and
cooled at room temperature for 20 minutes. Slides were then washed once with
1xPBS, and twice with 1XPBS/0.3% Triton-X. Slides were then placed into a
staining chamber. Primary antibodies (Table 2) were diluted in a 1xPBS/0.3%
Triton-X/1% BSA solution, and then 200µL of this solution was added to each
slide. Slides were incubated overnight at 4°C. The following morning, slides
underwent 3, 5-minute washes with 1xPBS/0.3%Triton-X. Secondary antibodies
(Table 3) were diluted in a 1xPBS/0.3% Triton-X/1% BSA solution, and then
200µL of this solution was added to each slide. Slides were then incubated in the
dark at room temperature for 1 hour. Following this incubation, slides underwent
3, 5-minute washes with 1xPBS/0.3%Triton-X. 500µL of DAPI was then added to
each slide, and incubated for 5 minutes. Slides were then washed twice with
1xPBS/0.3%Triton-X for 5 minutes each, then washed another two times with
1xPBS for 5 minutes each. Slides were then coverslipped and prepared for
microscopy.
Microscopy for immunofluorescence was carried out using the Leica DMI 6000b
automated inverted microscope (Leica Biosystems). Images were captured using
Openlab Software (v5.0 Improvision) and then transferred to the Volocity
program for further analysis, processing, and cell counting. Using the Volocity
software, the correct pixel/µm was set and scale bars were positioned onto the
corresponding image. Cell counts were performed on multiple sections from each
sample to acquire a global average, and performed on three to four biological
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replicates. The percentage of cells expressing the protein of interest was
determined by comparing the number of cells positive for the protein of interest to
the total number of DAPI-positive cells. An unpaired students t-test was then
used to determine if the percentage of cells expressing the protein of interest was
significantly different (p<0.05) between control and knockout mice.

2.7 Analysis of cholesterol abundance
Cholesterol levels in the forebrains from P14 AtrxFoxG1Cre and control mice were
measured by the Metabolic Phenotyping Laboratory at Robarts Research
Institute (Western University, London, Ontario, Canada). Whole mouse-brains
were isolated from P14 AtrxFoxG1Cre and control mice as described above, and
flash-frozen in dry ice. Brains were then transported to Brian Sutherland at the
Metabolic Phenotyping Laboratory for further processing.
Weights of each brain sample were initially recorded, followed by mincing with a
scalpel and transferred to a glass tube. Tissue lipids were extracted using the
Folch extraction method (Folch et al., 1957). First, 2.2mL of methanol was added
to each tube containing minced brain samples and incubated for 1 hour at room
temperature, followed by the addition of 4.4mL of chloroform.
A radioactive tracer was then incorporated into each sample to allow for lipid
recovery analysis. This was achieved by adding 400µL of a 0.1µCi/mL stock of
3H-Cholesterol Oleate to each sample. In parallel, 400µL of this isotope was
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aliquoted, in duplicate, into scintillation vials to allow for counts added
calculations. Counts added allows us to determine the value of 100% recovery.
Samples were then mixed with the isotope, and incubated at 4°C for 24-48 hours
to achieve total lipid extraction. The samples were filtered using Whatman paper
into a fresh glass tube. The original glass tube was then rinsed with 0.9mL of a
2:1 ratio of chloroform:methanol, and then filtered through Whatman paper into
the new glass tubes, followed by the addition of 1.5mL saline and incubated for
1-2 hours at room temperature. The combination of saline and methanol allows
for the separation of the chloroform containing the extracted lipids, from the rest
of the solution. Using a Pasteur pipette, the chloroform fraction was removed and
then placed into a fresh glass tube and made up to a 10mL solution with
chloroform.
To calculate the abundance of cholesterol in each sample, two separate assays
were performed to assess total cholesterol levels, and free cholesterol levels.
First, a solution containing a combination of Triolein and cholesterol standard,
and diluted in isopropanol, was aliquoted in triplicate to calculate a standard
curve for each assay. Next, 50-200µL of each sample was aliquoted, in duplicate,
into separate glass tubes. Simultaneously, 0.5mL of each sample was aliquoted
into scintillation vials containing scintillation fluid, to calculate recovery efficiency.
Each sample and standard were dried under nitrogen to remove the presence of
chloroform. 500µL of 1% TritonX-100 was then added to each tube and
incubated for 1 hour at room temperature, followed by drying under nitrogen.
50µL deionized water was added to each tube to solubilize the sample, as the
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assays to assess cholesterol levels cannot be run on chloroform based samples.
Each sample was then placed into a 37°C water bath 15 minutes prior to running
each assay.
To calculate the abundance of total cholesterol and free cholesterol, standard kits
were used [Wako kits 439-17501, 435-35801 (Wako Diagnostics), respectively].
For each assay, 1mL of colour reagent solution (from the corresponding Wako
kit) was added to each sample and cholesterol standard. These solutions were
then mixed, and incubated for 15 minutes at 37°C. Follow this incubation,
samples were cooled down at room temperature for 5 minutes. The absorbance
of each sample and standard was then measured at a wavelength of 600nm
using the Beckman DU 640 Spectrophotometer (Beckman Coulter).
An X-Y scatter plot was constructed placing the cholesterol standard values on
the Y-axis, and the corresponding absorbance values on the X-axis. A line of
best fit was then calculated in excel to determine the equation of the line. The
measured absorbance of each sample was inputted into this equation to
determine their subsequent concentration. Mean values of total cholesterol and
free cholesterol from control and AtrxFoxG1Cre samples were calculated, and the
abundance of cholesterol esters is calculated by subtracting free cholesterol from
total cholesterol. Unpaired students t-test was then used to determine if
cholesterol concentrations between control and AtrxFoxG1Cre samples were
significantly different (p<0.05).
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3

Results

3.1 Transcriptional profiling of the postnatal AtrxFoxG1Cre
forebrain reveals a decrease in myelin-specific gene
expression
The ATRX chromatin remodeling protein is a known regulator of gene
expression; therefore, to examine the gene expression profile in the developing
mouse forebrain in the absence of ATRX, a microarray was carried out on P17
AtrxFoxG1Cre and littermate-matched control mouse forebrains. It was determined
that gene expression was significantly changed in AtrxFoxG1Cre mice compared to
littermate-matched control mice if the fold-change was upregulated, or
downregulated by 1.3 fold (p<0.05). Examination of the P17 microarray data
revealed that ten of the top fifty-downregulated genes in AtrxFoxG1Cre mice are
genes implicated in oligodendrocyte development and CNS myelination (Figure
6A). Furthermore, GO analysis of significantly downregulated genes (-1.5 fold;
p<0.05) revealed that genes involved in various aspects of myelination were of
the top significantly downregulated genes in the P17 AtrxFoxG1Cre forebrain (Figure
6C). To determine the total number, and identity of the myelin-specific genes that
are significantly downregulated in P17 AtrxFoxG1Cre mice, the P17 microarray was
compared to an RNA-sequencing transcriptome database of glia, neurons, and
vascular cells of the cerebral cortex (Zhang et al., 2014). Using this database,
one can determine which genes are expressed, and at what concentration in a
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specific cell type compared to all other cell types in the cerebral cortex. Here, we
sought to determine the identity of genes specifically expressed in mature
myelinating OLs, as these cells are responsible for the development of the myelin
sheath, and compare this gene set to the significantly downregulated genes from
the P17 microarray. First, a list depicting genes enriched in myelinating OLs
compared to all other neuronal cells was constructed using the RNA-sequencing
database (Zhang et al., 2014). Furthermore, a 4-fold cutoff was set to narrow the
set of genes that are truly specific to myelinating OLs. This set of genes was then
compared to significantly downregulated genes (-1.3 fold; p<0.05) from the P17
microarray to determine how many of those downregulated genes were in fact
myelin-specific genes. It was determined that 76 myelin-specific genes were
significantly downregulated in P17 AtrxFoxG1Cre mice compared to their control
counterparts (Figure 6B).
Validation of the gene expression changes from the P17 microarray was
performed by qRT-PCR on cDNA extracted from P20 AtrxFoxG1Cre and control
forebrain samples. It was determined that expression of several myelin-specific
genes, was downregulated in P20 AtrxFoxG1Cre mice compared to littermatematched controls, thereby confirming the P17 microarray data (Figure 6D).
Taken together, this data suggests that ATRX may be an important factor for
proper myelin formation in the mouse brain.
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Figure 6. Transcriptional profiling of genes from P17 AtrxFoxG1Cre microarray
revealed a significant decrease in expression of myelin-specific genes
compared to littermate-matched controls.
A) Heat-map displaying the top fifty-downregulated genes in P17 AtrxFoxG1Cre
mice compared to controls. B) Heat-map displaying the top downregulated
oligodendrocyte-specific genes in P17 AtrxFoxG1Cre mice compared to controls. C)
GO-analysis of downregulated genes in P17 AtrxFoxG1Cre mice. D) qRT-PCR of
myelin-specific genes from P20 AtrxFoxG1Cre mice. Expression of each gene was
normalized to Gapdh. N=2. Error bars represent range of expression for two
biological replicates.
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3.2 Loss of ATRX from the mouse forebrain results in
hypomyelination
Next, we set out to determine if the decrease in myelin-specific gene expression
observed in P20 AtrxFoxG1Cre mice, results in a defect in myelin sheath
development. To address this matter, P20 AtrxFoxG1Cre and littermate-matched
control mouse brains were processed for western blot analysis and
immunofluorescence staining. To determine if loss of ATRX has a deleterious
effect on myelin-specific protein expression, western blot analysis of the myelinspecific markers CNP, MOG, MBP, and MAG was carried out using protein that
was isolated from P20 mouse forebrains. It was determined that protein
expression of CNP, MOG, MBP, and MAG was significantly reduced in P20
AtrxFoxG1Cre forebrains compared to littermate-matched controls (Figure 7A and
7B). Additionally, immunofluorescence co-staining of MBP and MOG was carried
out on whole-brain cryosections from P20 AtrxFoxG1Cre and littermate-matched
control mice to analyze the abundance and expression pattern of myelin in the
mouse forebrain. It was observed that expression of both MBP and MOG was
significantly decreased in the corpus callosum (a white-matter-rich area of the
brain) of P20 AtrxFoxG1Cre mice compared to their control counterparts (Figure
7C). This finding was also observed in the cerebral cortex, as MBP and MOG
expression were both significantly reduced and sparser in P20 AtrxFoxG1Cre mice
compared to littermate-matched control mice (Figure 7C). These findings
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Figure 7. Expression of myelin-specific proteins is significantly reduced in
P20 AtrxFoxG1Cre mice compared to littermate-matched controls.
A) Western blot of ATRX, INCENP, CNP, MBP, MOG, MAG, and Actin from
forebrain samples of P20 AtrxFoxG1Cre and control mice. B) Quantitative analysis
of western blot. ATRX was normalized to INCENP, whereas CNP, MBP, MOG,
and MAG were normalized to Actin. N=4. Error bars represent ± standard error of
the mean (±SEM). *p<0.001. C) Immunofluorescence staining of MBP and MOG
in P20 AtrxFoxG1Cre and control corpus callosum and cerebral cortex. N=3. Scale
bar represents 70µm. DAPI stains the nucleus of the cell.
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illustrate that loss of the ATRX chromatin remodeling protein results in severe
hypomyelination in the mouse forebrain, and therefore we can conclude that
ATRX is required for proper myelination in the CNS.

3.3 Hypomyelination in the AtrxFoxG1Cre mouse forebrain is
not due to a reduction in neuronal cell number
The hypomyelination phenotype seen in the forebrains of P20 AtrxFoxG1Cre mice
may be the result of a reduction in the total number of neurons that can be
myelinated. To address the possibility that the total number of neurons is
decreased in P20 AtrxFoxG1Cre mice, immunofluorescence staining of the neuronspecific marker neuronal nuclei antigen (NeuN) was carried out on whole-brain
cryosections of P20 AtrxFoxG1Cre and control mice. Co-staining of P20 AtrxFoxG1Cre
and control mouse brain cryosections for DAPI and NeuN allowed us to
determine the percentage of neurons in the mouse forebrain. Counts of DAPIpositive cells revealed that the total number of cells in a set area is equal
between P20 AtrxFoxG1Cre and control mice (Figure 8A and 8B). Furthermore, it
was determined that approximately 76% of DAPI-positive cells are neurons in
P20 control mouse forebrains, and this percentage of neurons was found to be
equivalent in the P20 AtrxFoxG1Cre mouse forebrain (Figure 8A and 8C). As
neuronal cell number is unchanged between P20 AtrxFoxG1Cre and litter-matched
control mice, we can deduce that the hypomyelination phenotype observed
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Figure 8. Hypomyelination is not due to a reduction in the number of
neurons in the mouse brain.
A) Immunofluorescence staining of NeuN and ATRX in the cerebral cortex of P20
AtrxFoxG1Cre and control mice. N=3. Scale bar represents 70µm. B) Cell counts
were performed to analyze the total number of DAPI-positive cells per unit area.
C) Cell counts were performed to analyze the percentage of NeuN-positive cells
compared to DAPI-positive cells. N=3. Error bars represent ±SEM. p>0.05. DAPI
stains the nucleus of the cell.
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in AtrxFoxG1Cre mice is not due to a reduction in the number of neurons, but due to
a defect in the initiation of myelination by OLs.

3.4 Oligodendrocyte precursor cell production is unchanged
in AtrxFoxG1Cre mice at birth
Onset of myelination may be impeded by multiple factors including deficiencies in
OPC production, proliferation, and/or differentiation into postmitotic immature
OLs. We first wanted to assess OPC production and morphology in AtrxFoxG1Cre
mice at birth. Microarray analysis performed on P0.5 mouse forebrain samples
revealed that expression of two known OPC markers, Pdgfrα and Cspg4 [1.16
fold (p>0.05) and -1.11 fold (p>0.05) respectively], was unchanged in P0.5
AtrxFoxG1Cre mice compared to littermate-matched controls. To confirm that the
expression of these OPC markers is unchanged when ATRX is absent, qRTPCR was carried out on cDNA from P0.5 AtrxFoxG1Cre and littermate-matched
control mouse forebrains. It was determined that expression of both Pdgfrα and
Cspg4 was unchanged in P0.5 AtrxFoxG1Cre mice compared to controls (Figure
9A). To determine if this effect is observed at the protein level, western blot analysis and immunofluorescence staining of the OPC marker PDGFRα, was
performed. Western blot analysis revealed that protein expression of PDGFRα
was unchanged between P0.5 AtrxFoxG1Cre and littermate-matched control mice
(Figure 9B and 9C). OPC production was further examined by performing
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Figure 9. Expression of OPC markers is unchanged in P0.5 AtrxFoxG1Cre mice
compared to littermate-matched controls.
A) qRT-PCR of Atrx, Pdgfrα, and Cspg4 from P0.5 AtrxFoxG1Cre mice. Expression
of each gene was normalized to Gapdh. N=3. Error bars represent ±SEM.
*p<0.001 for Atrx. p>0.05 for Pdgfrα, and Cspg4. B) Western blot of ATRX,
PDGFRα, and INCENP from forebrains of P0.5 AtrxFoxG1Cre and control mice. C)
Quantitative analysis of western blot. ATRX, and PDGFRα was normalized to
INCENP.

N=4. Error bars represent ±SEM. p>0.05. D) Immunofluorescence

staining of PDGFRα in the cerebral cortex of P0.5 control and AtrxFoxG1Cre mice.
Scale bar represents 70µm. DAPI stains the nucleus of the cell E) Quantitative
analysis of the percentage of PDGFRα-positive cells compared to total number of
DAPI-positive cells. N=3. Error bars represent ±SEM. p>0.05
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immunofluorescence staining for PDGFRα on P0.5 whole-brain cryosections. To
assess OPC production capability in P0.5 AtrxFoxG1Cre mice compared their
control counterparts, cell counts for PDGFRα-positive cells were performed in the
cerebral cortex, as the majority of OPCs populating the brain at birth arise from
the cerebral cortex (Kessaris et al., 2006). It was determined that the percentage
of OPCs in the cerebral cortex was similar between P0.5 AtrxFoxG1Cre and
littermate-matched control mice (Figure 9D and 9E). These findings infer that
ATRX loss from the forebrain does not affect OPC production/maintenance, and
therefore must have an alternative role in myelin sheath formation.

3.5 Differentiation of oligodendrocyte precursor cells into
immature oligodendrocytes is hindered in the absence
of ATRX
A potential mechanism that ATRX may have in the myelination process is the
regulation of OPC differentiation into premyelinating iOLs. To study this
possibility, immunofluorescence staining of APC and OLIG2 was carried out on
whole-brain cryosections from P10 AtrxFoxG1Cre and littermate-matched control
mice. It was determined that the number of APC/OLIG2-positive cells was
significantly reduced in the corpus callosum of P10 AtrxFoxG1Cre mice compared to
littermate-matched control mice (Figure 10A and 10B). These data
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Figure 10. The number of APC/OLIG2-postive cells is significantly
decreased in P10 AtrxFoxG1Cre mice compared to littermate-matched
controls.
A) Immunofluorescence staining of APC and OLIG2 in the corpus callosum of
P10 AtrxFoxG1Cre and control mice. B) Cell counts were performed to determine
the percentage of APC/OLIG2-positive cells per DAPI-positive cells. N=3. Scale
bar represents 100µm. Error bars represent ±SEM. *p<0.05. DAPI stains the
nucleus of the cell.
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strongly suggests that ATRX is required for OPC differentiation into iOLs.
Although differentiation of OPCs is impeded in the absence of ATRX, the defect
in differentiation does not fully explain the severe hypomyelination phenotype
seen in P20 AtrxFoxG1Cre mice; therefore, ATRX must also be required during the
final stage of myelin sheath development by influencing maturation of iOLs into
myelinating OLs.

3.6 Cholesterol biosynthesis is unaffected in the P14
AtrxFoxG1Cre mouse forebrain
Cholesterol biosynthesis is crucial to myelination as 26% of the myelin sheath is
composed of cholesterol. Analysis of the P17 microarray revealed that several
genes involved in cholesterol biosynthesis were downregulated in the P17
AtrxFoxG1Cre mouse forebrain compared to age-matched controls (data not
shown). Therefore, we hypothesized that ATRX was required for cholesterol
biosynthesis, as loss of ATRX may cause a decrease in cholesterol levels and
consequently cause a delay in myelin formation. To study ATRX and its effects
on cholesterol biosynthesis, cholesterol levels were measured in 14 day-old mice
(peak of cholesterol biosynthesis in the mouse brain) in collaboration with Brian
Sutherland at the Robarts Research Institute. This was accomplished by first,
isolating lipids from the forebrain, and then using standard kits to quantify total
cholesterol as well as free cholesterol levels. Total cholesterol, and free
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Figure 11. Cholesterol levels are unchanged in the absence of ATRX from
P14 mice.
Total cholesterol, free cholesterol, and cholesterol ester levels. N=4. Error bars
represent ±SEM. p>0.05.
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cholesterol levels were found to be unchanged in P14 AtrxFoxG1Cre mice compared
to age-matched controls (Figure 11). Overall, these results suggest that ATRX
does not influence myelination by regulating cholesterol biosynthesis.

3.7 Generation of a novel mouse model to study the
oligodendrocyte-specific function of ATRX
Intricate interaction between several key cell types, such as OLs, astrocytes, and
neurons is necessary for proper myelin formation; therefore, a disruption in any
of these cell types can lead to a hypomyelinated phenotype. Because OLs are
the glial cells that myelinate neurons in the CNS, we wanted to determine if
ATRX has an OL-specific effect on myelin sheath formation. To study the
function of ATRX within OLs, transgenic male mice that express Cre
recombinase under control of the Cnp promoter (Lappe-Siefke et al., 2003) were
mated with female mice containing loxP sites flanking exon 18 of the Atrx gene
(Bérubé et al., 2005). This cross results in the deletion of Atrx specifically from
OLs (referred to as AtrxCnpCre) beginning at approximately P5. It was determined
that the proportion of oligodendrocytes defined by OLIG1-positive cells, was
unchanged between P20 AtrxCnpCre and littermate-matched control mice (Figure
12A and 12B). Immunofluorescence co-staining of OLIG1 and ATRX on
cryosections of P20 AtrxCnpCre and littermate-matched control mouse brains
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Figure 12. ATRX expression is successfully lost from OLs in AtrxCnpCre
mice.
A) Immunofluorescence staining of OLIG1 and ATRX in the corpus callosum of
P20 AtrxCnpCre and control mice. N=3. Scale bar represents 70µm. DAPI stains
the nucleus of the cell. B) Cells counts that assess the proportion of the number
of OLIG1-positive cells per DAPI-positive cells per unit area. C) Cell counts that
assess the proportion of the number of ATRX-positive cells per OLIG1-positive
cells. Cell counts were performed on an N=2. Errors bars represent the range of
two biological replicates.
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confirmed that Atrx was successfully deleted from OLs in AtrxCnpCre mice (Figure
12A and 12C). These results suggest that this mouse model is a good model to
study the OL-specific effects of ATRX in myelination.

3.8 Oligodendrocyte-specific deletion of ATRX does not
affect myelin formation in the mouse brain
As ATRX has been shown to directly regulate gene expression, it was
hypothesized that ATRX may influence CNS myelination by regulating the
expression of myelin-specific genes in mature myelinating OLs. P20 AtrxCnpCre
and littermate-matched control mice were utilized to assess the OL-specific
function of ATRX.
Characterization of the mouse phenotype was first performed to assess if loss of
ATRX from OLs results in abnormal physical traits compared to age-matched
controls. It was determined that P20 AtrxCnpCre and littermate-matched control
mice appeared proportionally similar to one-another in their overall body length
(Figure 13A and 13B)
To determine if loss of ATRX from OLs results in hypomyelination in the mouse
brain, we performed western blot analysis of the myelin markers MOG, MBP, and
MAG from protein isolated from whole forebrains of P20 AtrxCnpCre and control
mice (Figure 14A). It was found that the expression of MOG and MBP was
unchanged in P20 AtrxCnpCre mice compared to littermate-matched controls
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Figure 13. Characterization of the P20 AtrxCnpCre and littermate-matched
control mouse phenotypes
A) Images of P20 control and AtrxCnpCre mice. B) Measurements of mouse
lengths (mm). N=4. Error bars represent ±SEM. p>0.05
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(Figure 14B). Additionally, this finding was corroborated by immunofluorescence
co-staining of MBP and MOG on brain cryosections. Immunofluorescence
staining revealed that expression of MBP and MOG in both the corpus callosum
and the cerebral cortex was analogous between P20 AtrxCnpCre and littermatematched controls (Figure 14C). This finding brings us to the conclusion that the
abundance of myelin is unchanged in mice that lack ATRX specifically from OLs.
Taken together, these results strongly suggest that myelin sheath formation does
not require ATRX within OL cells and therefore does not directly regulate myelinspecific gene expression. These findings imply that ATRX must be required in a
different cell type to allow for proper formation of the myelin sheath in the CNS.
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Figure 14. Expression of myelin-specific proteins is unchanged between
P20 AtrxCnpCre mice compared to littermate-matched controls.
A) Western blot of MOG, MBP, and Actin from forebrains of P20 AtrxCnpCre and
control mice. B) Quantitative analysis of western blot. MBP, and MOG were
normalized to Actin. N=3. Error bars represent ±SEM. p>0.05. DAPI stains the
nucleus of the cell. C) Immunofluorescence staining of MBP and MOG in the
corpus callosum and cerebral cortex of P20 AtrxCnpCre and control mice. N=3.
Scale bar represents 70µm.
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4

Discussion

4.1 Summary of results
The ATRX chromatin remodeling protein has been found to be an essential factor
for proper brain development, as mutations within the human ATRX gene result
in ATR-X syndrome. ATR-X is a neurodevelopmental disorder characterized by
cognitive defects, seizures, and microcephaly (Gibbons, 2006). Furthermore,
recent MRI studies revealed that ATR-X syndrome patients also display varying
degrees of white matter abnormalities, and delayed myelination (Wada et al.,
2013). Studies have implicated ATRX in several cellular processes including
regulation of the epigenetic environment of heterochromatin, mitosis, and gene
expression. The present study identifies not only a novel function of ATRX, but
also an additional regulator of myelination within the mouse CNS.
To assess the changes in gene expression when ATRX is lost from P17 mouse
forebrains, a microarray was carried out. Transcriptional profiling of the
microarray revealed that expression of several myelin-specific genes was
significantly downregulated in P17 AtrxFoxG1Cre mouse forebrains compared to
age-matched controls. In addition, GO-analysis of significantly downregulated
genes in the forebrain of P17 AtrxFoxG1Cre mice revealed that genes involved in
several processes of myelination were of the most significantly downregulated
genes. To determine if the reduction of myelin-specific gene expression in the
AtrxFoxG1Cre forebrain correlated with a decrease in myelin formation, we analyzed
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the forebrains of AtrxFoxG1Cre and littermate-matched control mice at postnatal day
20, as the majority of neurons have been fully myelinated by this time. It was
determined that loss of ATRX from the P20 forebrain results in significant
hypomyelination in both the cerebral cortex and corpus callosum; two areas of
the brain that are highly abundant in white matter and crucial for proper cognition.
Therefore, we can conclude that ATRX is in fact required for proper myelination
within the CNS.
Hypomyelination in the brain can be the result of numerous consequences,
including a reduction in the total number of axons that can potentially be
myelinated. It was resolved that neuronal cell numbers were equivalent between
P20 AtrxFoxG1Cre and control samples, implying that the observed hypomyelination
phenotype in the P20 AtrxFoxG1Cre forebrain is due to a defect in myelin
development and not to due a reduction in the number of myelinated neurons.
I next wanted to determine the mechanism by which ATRX acts to allow for
myelin formation to take place. I first analyzed the production and morphology of
OPCs at P0.5, as a decrease in the number of OPCs or malfunction of OPCs
would result in a myelination defect. It was established that OPC production and
morphology is unaffected in the absence of ATRX, suggesting that ATRX is
required further downstream in the OL-development pathway. A possible
mechanism of ATRX in myelin sheath formation is its potential requirement for
OPC differentiation into premyelinating iOLs. It was determined that loss of ATRX
from the P10 AtrxFoxG1Cre mouse forebrain results in a decrease in the number of
premyelinating iOLs. A defect in OPC differentiation can result in a decrease in
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myelination as it limits the number of OLs that can myelinate axons; however, the
decrease in the number of immature OLs when ATRX is absent, does not
correlate with the severe hypomyelination phenotype observed in the P20
AtrxFoxG1Cre mouse forebrains. Therefore is it postulated that ATRX is required not
only for OPC differentiation into iOLs, but is also required for the maturation of
iOLs into myelinating OLs.
The myelin sheath is a modified plasma membrane that is enriched with
cholesterol. Cholesterol is a major constituent of the myelin sheath (~26% of the
dry weight of myelin), and previous studies have shown that mice with OLs that
cannot synthesize cholesterol, display a delay in myelin sheath production
(Norton and Cammer, 1984; Saher et al., 2005). This led us to hypothesize that
proper myelin sheath formation may be influenced by ATRX through the
regulation of cholesterol synthesis.
Cholesterol levels were assessed at P14 as this time point represents the peak
of myelination in mice. It was determined that the abundance of total cholesterol,
free cholesterol, and cholesterol esters was analogous between P14 AtrxFoxG1Cre
and control mouse forebrains. In addition, it was determined that the abundance
of total cholesterol was similar to that of free cholesterol, and the presence of
cholesterol esters was negligible. Cholesterol present in the brain is synthesized
internally; therefore, the cholesterol found within the brain consists strictly of free
cholesterol with no presence cholesterol esters (Baumann and Pham-Dinh, 2001;
Quarles, 2005). These findings allow us to conclude that ATRX does not regulate
CNS myelin sheath formation by influencing cholesterol biosynthesis.
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The myelin sheath in the CNS is generated by a subset of glial cells known as
OLs. Regulation of myelin-specific gene expression within OLs is still poorly
understood. In recent years, one such factor has emerged as a potential “master
regulator” of myelin-specific gene expression. MRF is a transcriptional regulator
that has been found to be crucial for myelin sheath formation. Ablation of MRF
from OLs impedes myelin sheath formation almost completely; however,
induction of MRF in OPCs can promote premature myelination (Emery et al.,
2009).
As ATRX has been implicated in the regulation of gene expression, I
hypothesized that ATRX may act in a similar fashion to MRF, and act as a direct
transcriptional regulator of several myelin-specific genes that are required for
myelin sheath formation. To address this question, I first developed a novel
mouse model in which Atrx is completely eradicated specifically from OL-lineage
cells (AtrxCnpCre). To our surprise, analysis of both the cerebral cortex and corpus
callosum revealed that myelination occurred normally in P20 mice lacking ATRX
specifically from OLs; suggesting that ATRX does not directly regulate myelinspecific gene expression in OLs.
Taken together, these results allow for the rejection of my hypothesis. These
findings illustrate that ATRX is required for myelin sheath formation in the CNS
by not only regulating OPC differentiation, but also by influencing the maturation
of iOLs into myelinating OLs, and does so through an OL non cell-autonomous
mechanism.
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4.2 ATRX acts in a non cell-autonomous role to regulate
myelin sheath formation
Initiation of myelin sheath formation requires numerous intracellular and
extracellular mechanisms to act synergistically to allow for proper ensheathment
of axons. Myelination in the central nervous system requires precise interaction
of several cell types, including OLs, astrocytes, microglia, and neurons. It was
hypothesized that ATRX may regulate the expression of myelin-specific genes
within OLs, as these cells are the subtype of glial cell that myelinate axons;
however, it was determined that myelination occurs normally when ATRX is lost
from OLs, suggesting that ATRX must be required within in different cell
population to promote myelination.

4.2.1

ATRX may act to control neuronal-specific gene
expression to regulate myelin sheath formation

Myelination is complex and tightly regulated process that is influenced not only
by OL-intrinsic factors, but by axonal activity, secreted ligands, and expression of
axonal surface ligands as well (Emery, 2010). Preliminary findings from our lab
suggest that ATRX may have a neuronal-specific function in the regulation of
myelination.
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Female mice containing loxP sites flanking exon 18 of the Atrx gene were mated
with male transgenic male mice that express Cre recombinase under control of
the neuronal-specific marker, calcium/calmodulin-dependent protein kinase II
(CamkII) promoter (Chen et al., 2001). The resulting male progeny (AtrxCamkIICre)
from this cross lacks ATRX specifically from postmitotic neurons. Coimmunofluorescence staining for ATRX and NeuN demonstrated that at P20,
ATRX has yet to be lost from postmitotic neurons in AtrxCamkIICre mice (Appendix
A); therefore, these mice cannot be used to study a potential neuronal-specific
function of ATRX on myelin sheath formation. Conversely, it was determined that
by 8-weeks of age, ATRX has been successfully lost from neurons in AtrxCamkIICre
mice (Appendix A), and therefore can be used to study the neuronal-specific
effect of ATRX on myelin sheath maintenance at a later age.
Preliminary evidence suggests that myelin sheath maintenance is disrupted in
AtrxCamkIICre mice at 3-months of age, as expression of myelin-specific markers
were found to be significantly reduced in AtrxCamkIICre mice compared to controls
when analyzed by western blot and immunofluorescence staining (Appendix B).
These preliminary findings suggest that ATRX has a neuronal-specific effect on
myelin sheath maintenance, and therefore may have a neuronal-specific effect
on myelin sheath formation; however, further experimentation will need to be
carried out to resolve this theory.
ATRX may therefore regulate expression of genes that code for secreted factors
and/or neuronal-specific factors that function by promoting OPC differentiation
into iOLs, as well as maturation of iOLs into myelinating OLs. It has been found

86

that OPC differentiation into premyelinating iOLs relies on signaling molecules
from the targeted axonal cell body. One such mechanism is the Notch-1 signaling
pathway that is activated through binding of secreted axonal molecule
F3/contactin (Hu et al., 2003). The Notch-1 signaling pathway can both positively
and negatively regulate OPC differentiation. Axonally derived F3/contactin binds
the Notch-1 receptor on OPCs, and promotes OPC differentiation. This is
achieved as F3/contactin binding to Notch-1 promotes the binding of downstream
cytoplasmic target Deltex-1 (DTX-1) to the Notch intracellular domain (NICD)
protein. This binding causes cleavage of NICD which allows it to translocate into
the nucleus, where it then positively regulates the expression of a selection of
myelin-specific genes, and thus OPC differentiation into immature premyelinating
OLs (Hu et al., 2003). On the other hand, the Notch-1 signaling pathway can
inhibit differentiation, as Jagged-1 binding to Notch-1 inhibits OPC differentiation
by activating Hes1 and Hes5 expression (Wang et al., 1998; Kondo and Raff,
2000).
In addition to the promoting the differentiation of OPCs, axonal signaling
molecules have also been implicated in initiating the onset of myelination. One
such molecule that has been shown to promote myelination is laminin-α2
(Morissette and Carbonetto, 1995; Colognato et al., 2002). Laminin-α2 binds the
OL-specific β-1 receptor, thus promoting the dephosphorylation of the Fyn
tyrosine kinase. This dephosphorylation event results in the activation of ILK,
PINCH, and α-parvin leading to the polymerization of actin filaments, resulting in
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the extension of the OL filopodia and allowing contact initialization with
unmyelinated axons (Liang et al., 2004; Bauer et al., 2009; Hu et al., 2009).
A gene expression microarray was performed to assess the expression changes
between P0.5 AtrxFoxG1Cre and control mice as well as P17 AtrxFoxG1Cre and control
mice. Analysis of these microarrays revealed that expression of contactin-1 (also
known as the F3 neural cell surface protein) was slightly decreased in both P0.5
and P17 AtrxFoxG1Cre mice [-1.17 fold (p>0.05) and -1.073 (p>0.05) respectively]
compared to controls. It was also revealed that laminin-α2 was also slightly
decreased in P17 AtrxFoxG1Cre mice [-1.14 fold (p>0.05)] compared to controls.
Although the expression changes seen are not significant, validation by qRTPCR should be performed to reveal the true expression changes of these genes,
as microarrays have long been known to have inaccuracies.
A potential mechanism for ATRX is that it may be required to positively regulate
the expression of contactin-1 and/or laminin-α2, thus promoting OPC
differentiation, and/or the maturation of immature OLs into myelinating OLs.
ATRX may achieve this by directly influencing contactin-1 and laminin-α2 gene
expression as described previously (Levy et al., 2014), or through its interaction
with MeCP2, CTCF, or Daxx (Drané et al., 2010; Goldberg et al., 2010; Kernohan
et al., 2010; Lewis et al., 2010; Wong et al., 2010; Kernohan et al., 2014).
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4.2.2

Astrocyte influence in CNS myelination

The majority of studies that examine the mechanisms of CNS myelination have
focused primarily on the OL-specific effects, as well as the axonal influences that
promote myelin sheath formation. It has been documented that in addition to OLs
and neurons, astrocytes are also a key contributor to myelination in the CNS.
Astrocytes are the most abundant and diverse subpopulation of glial cell found in
the CNS, and are primarily involved in the organization and maintenance of brain
structure and function (Sofroniew and Vinters, 2010; Lundgaard et al., 2014).
Astrocytes have been found to be required for neuronal migration and process
extension during brain development, as well as being crucial for neuronal survival
(Powell and Geller, 1999; Wagner et al., 2006). In addition, astrocytes have also
been found to be required not only for OL-development, but for myelination
initiation and maintenance as well.
Astrocytes have been shown to influence OPC differentiation and myelin sheath
formation through its interactions with OLs and neurons. Recently, it was
revealed that through two separate mechanisms, OPC differentiation is
influenced by the release of the promyelinating cytokine, leukemia inhibitory
factor (LIF) from astrocytes (Fischer et al., 2014). OL and astrocyte co-culture
experiments determined that the tumor necrosis factor (TNF) derived from OLs,
activates TNFR2 on astrocytes. Activation of TNFR2 then results in the PI3K-Aktdependent secretion of LIF, leading to an increase in expression of myelinspecific factors (Fischer et al., 2014). In addition, Ishibashi and colleagues further
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determined that during development, neuronal activity simulates the release of
ATP, upon which signals neighboring astrocytes to release LIF (Ishibashi et al.,
2006). As ATRX is a known regulator of gene expression, loss of ATRX
specifically from astrocytes may alter the expression pattern of several of these
positive and negative regulators, and thereby potentially modifying the
myelination phenotype.
It has been shown that loss of ATRX from the mouse forebrain results in an
increase in the number of reactive astrocytes (McConkey unpublished). This
increase may result in hypomyelination as it has been found that an increase in
the number of reactive astrocytes can have detrimental effects in brain
development. It has been discussed that an increase in reactive astrocytes can
amplify the production of cytokines leading to an exacerbation of inflammation. In
addition, reactive astrocytes can increase the release of toxic materials such as
glutamate and reactive oxygen species (ROS) (Sofroniew and Vinters, 2010;
Lanciotti et al., 2013). This production and release of toxic substances can result
in damage to the myelin sheath leading to increased neurodegeneration.
ATRX has been found to be important for proper NPC proliferation and
differentiation. Loss of ATRX was found to result in premature NPC differentiation
leading to an increase in the number of outer radial glia, as well as an increase in
the generation of postmitotic projection neurons (Ritchie et al., 2014). As radial
glial cells are multipotent progenitor cells, they have the capability to differentiate
into various cell types including astrocytes (Vaccarino et al., 2007). It is therefore
a possibility that premature differentiation of NPCs due to a loss of ATRX, may
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also result in an increase in the number of reactive astrocytes; however further
experimentation is required to assess this hypothesis.

4.2.3

Systemic regulation and growth factor influence of
myelin sheath formation in the CNS

CNS myelination is not only regulated by cell-cell communication between OLs
and neurons as well as between OLs and astrocytes, but is also regulated by the
IGF-1 growth factor, and systemically by circulating T4.
T4 and its activated version T3 are tyrosine-based hormones that are produced
by the follicular cells of the thyroid gland, and have been implicated to be crucial
factors in proper brain development. It has been established that hypothyroidism
results in mental retardation and delayed myelination (Dussault and Ruel, 1987);
two characteristics observed in ATR-X syndrome patients. Thyroid hormones
have been determined to be crucial for both differentiation and maturation of OLs
in the CNS. T3 has been found to block OPC proliferation, therefore initiating
differentiation of OPCs into immature OLs (Baas et al., 1998; Park et al., 2001).
In addition, hypothyroidism impedes the onset of myelination by delaying the
expression of several crucial myelin-associated factors, including fatty acid αhydroxylase,

galactosyltransferase,

sialyl-transferase,

and

sulfotransferase

(Dussault and Ruel, 1987). Furthermore, thyroid hormones have been found to
directly regulate the expression of the myelin-specific genes, Mbp and Mag
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(Farsetti et al., 1991; Rodriguez-Peña et al., 1993). It was observed that induced
hypothyroidism in mice resulted in decreased MBP mRNA expression, and it was
further determined that the promoter region of Mbp is susceptible to thyroid
hormone binding, suggesting that Mbp expression is directly (at least partially)
regulated by thyroid hormones (Farsetti et al., 1991). These studies reveal that
thyroid hormones have a fundamental role in the development of the OL pathway
and the onset of myelination.
In addition to thyroid hormones, IGF-1 has also been found to be an important
regulator of CNS myelination. IGF-1 has been established as a significant factor
in the differentiation, maturation, and survival of OLs (Carson et al., 1993;
McMorris et al., 1993). Overexpression of IGF-1 in mice, revealed a substantial
increase in both the number of OLs, and the abundance of myelin (Carson et al.,
1993; Ye et al., 1995). On the other hand, mice lacking IGF-1 display a
significant reduction in the myelin-specific markers MBP and PLP at 3-weeks of
age, a characteristic of delayed myelination (Ye et al., 2002). In addition, it was
revealed that mice lacking the IGF1 receptor (IGF1R) from OLs displayed
significant reductions in overall brain size, number of OPCs, as well as a
reduction in the number of differentiated iOLs leading to a decrease in
myelination (Zeger et al., 2007). These findings strongly demonstrate that the
IGF-1/IGF1R signaling pathway is crucial for proper OL and myelin sheath
development.
It has been previously shown that loss of ATRX from the P20 mouse forebrain
and anterior pituitary, results in decreased circulating T4 and IGF-1 levels
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(Watson et al., 2013). In addition, it was also determined that loss of ATRX
results in decreased expression of the thyroid stimulating hormone (Tsh)
(Watson et al., 2013). TSH is made by thyrotropes, a population of cells that are
located in the anterior pituitary, and who directly influence the regulation of T4.
As these factors are known to be crucial for OL-development and myelination, a
potential mechanism of ATRX in myelin sheath formation, may be its requirement
for the transcriptional regulation of these factors through previously seen
mechanisms (Drané et al., 2010; Goldberg et al., 2010; Lewis et al., 2010; Wong
et al., 2010; Kernohan et al., 2014; Levy et al., 2014). It is still unclear whether
the loss of ATRX results in decreased levels of T4 and IGF-1 separately, or if the
decrease of IGF-1 is the result of T4 dysfunction, as it has been found that T4
can bind to the Igf-1 transcript and thus can regulate its expression (Wang et al.,
2010). Our group is currently addressing the role of ATRX in the regulation of T4
and IGF-1, and findings from this study may further elucidate the role of ATRX in
myelin sheath formation.

4.3 Future Directions
To address the hypotheses that ATRX may influence OPC differentiation and
maturation of iOLs through neuronal or astrocyte-specific effects, transgenic
mouse lines will be utilized to conditionally delete ATRX from postmitotic neurons
and from astrocytes in the CNS prior to myelin sheath formation.
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To assess the neuronal-specific function of ATRX, female mice containing loxP
sites flanking exon 18 of the Atrx gene will be crossed with transgenic male mice
containing the Cre recombinase gene downstream of the Nex promoter
(Goebbels et al., 2006). This cross will result in progeny (AtrxNexCre) that will have
a deletion of Atrx exclusively from postmitotic neurons beginning at
approximately E12.5 (Goebbels et al., 2006).
To assess the astrocyte-specific effect of ATRX, a mouse model to conditionally
deplete ATRX from astrocytes that has been previously characterized will be
used (McConkey unpublished). Female mice containing loxP sites flanking exon
18 of the Atrx gene were crossed with transgenic male mice containing the Cre
recombinase gene downstream of the glial high affinity glutamate transporter
(Glast) promoter. This cross results in progeny (AtrxGlastCreERT) that have a
deletion of Atrx exclusively from astrocytes upon administration of tamoxifen.
To address the myelination phenotype when ATRX is lost specifically from
neurons and astrocytes, identical experimental procedures as the ones
performed in section 3.2 of this thesis, will be carried out. Findings from these
experiments will allow us to establish if ATRX has a neuronal-specific and/or an
astrocyte-specific effect on myelin sheath formation in the CNS.
To identify extracellular factors that may be required for myelin sheath formation,
mass spectrometry will be performed on isolated cell co-culture media from
separate OPC/neuronal and OPC/astrocyte cell co-culture experiments, using
primary cells extracted from AtrxNexCre and control mice, as well as AtrxGlastCreERT
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and control mice. Mass spectrometry analysis of cultured medium from these
separate cell co-culture experiments will enable us to identify extracellular
signaling molecules that are required for myelination, as well as facilitate in the
detection of secreted molecules that are differentially expressed when ATRX is
lost from neurons and astrocytes.
In addition to secreted ligands, expression of intrinsic neuronal-specific and
astrocyte-specific factors that are essential for myelin sheath formation may also
be dysregulated in the absence of ATRX. To assess neuronal-specific and
astrocyte-specific gene expression changes when ATRX is lost from post-mitotic
neurons, RNA-seq will be carried out on RNA isolated from P5, P14, and P20
AtrxNexCre and control cortical neurons, as well as RNA isolated from P5, P14, and
P20 AtrxGlastCreERT and control astrocytes, that have been separated by
fluorescence-activated cell sorting (FACS). Cells from P5 mice will be used, as
OPC differentiation is highly active at this time. Cells from P14 mouse forebrains
will be used, as this time point represents the peak of myelination, and cells from
P20 mouse forebrains will be used, as the myelin sheath is highly abundant at
this time. Identification of dysregulated neuronal-specific and astrocyte-specific
genes, that code for factors implicated in myelination is essential as an ATRXdependent process may regulate the expression of these genes.
Comparative analysis of extracellular signaling ligands by mass spectrometry,
and analysis of differential gene expression by RNA-seq will allow us to identify
potential neuronal and astrocyte-specific targets whose expression may be
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regulated by ATRX. This data will allow us to generate additional hypotheses to
identify the exact molecular mechanism of ATRX in CNS myelination.
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Figure 15. Proposed model of ATRX and its potential mechanism in
myelination of neurons in the mouse CNS
ATRX may regulate the expression of neuron-specific genes such as
F3/contactin and/or laminin-α2, to influence oligodendrocyte precursor cell
differentiation and/or maturation of immature oligodendrocytes into myelinating
oligodendrocytes respectively (i). ATRX may also act to regulate astrocytespecific genes such as leukemia inhibitory factor (LIF) or other astrocyte-specific
genes (ASG), which would be required for oligodendrocyte precursor cell
differentiation (ii). An additional mechanism of ATRX is that it may act to regulate
the expression of thyroid stimulating hormone (Tsh) which then regulates the
expression

of

thyroid

hormones

development and myelination (iii).

(TH)

and

ultimately

oligodendrocyte
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5

Conclusions

The present study addresses a novel role of ATRX in the development of OLs
and myelin sheath formation in the CNS. It was determined that loss of ATRX
from the mouse forebrain results in hypomyelination, and that this phenotype is
due to a defect in OPC differentiation into iOLs, and iOL maturation into
myelinating OLs. Furthermore, it was resolved that ATRX does not have an OL
cell-autonomous role in myelination. It is suggested that ATRX influences myelin
sheath formation and maintenance by potentially regulating the expression of
neuronal-specific and/or astrocyte-specific factors that are required for
myelination, as well as potentially regulating circulating T4 and IGF-1 levels
(Figure 15). Elucidation of the role of ATRX in myelin production would present a
novel non cell-autonomous mechanism that regulates myelin formation.
Transcriptional regulation of neuronal-specific and astrocyte-specific genes that
code for factors that function by instructing OPC differentiation, and OL
maturation have yet to be fully elucidated; therefore, this discovery would be
beneficial, as it will further our understanding of the mechanisms involved in
myelination in the postnatal mouse forebrain. ATRX causes severe cognitive
deficits, seizures, and microcephaly, all of which are associated with loss of white
matter. These findings give the prospect of potentially finding a method to
alleviate hypomyelination defects in ATR-X patients, which may lead to
discoveries of potential therapies for ATR-X patients, as well as other myelin
relevant disorders such as multiple sclerosis, various leukodystrophies, and
neuropsychiatric disorders.
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Appendices

Appendix A. ATRX expression is retained in neurons in P20 AtrxCamkIICre
mice, but is lost from neurons in 3-month-old AtrxCamkIICre mice
Immunofluorescence staining of NeuN and ATRX in the cerebral cortex of P20
and 3-month-old AtrxCamkIICre and control mice. N=1. Scale bar represents 70µm.
DAPI stains the nucleus of the cell.
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Appendix B. Expression of myelin-specific proteins is reduced in 3-monthold AtrxCamkII mice compared to littermate-matched controls
A) Western blot of MOG, MBP, and Actin from forebrain samples of 3-month-old
AtrxCamkIICre and control mice. B) Quantitative analysis of western blot. MOG and
MBP were normalized to Actin. N=2. Error bars represent the range of
expression of two biological replicates. C) Immunofluorescence staining of MBP
and MOG in P20 AtrxFoxG1Cre and control corpus callosum and cerebral cortex.
N=1. Scale bar represents 70µm. DAPI stains the nucleus of the cell.

114

Curriculum Vitae
Name:

Matthew William Edwards

Post-secondary
Education and
Degrees:

The University of Western Ontario
London, Ontario, Canada
2007-2011 B.Sc. in Biology, Honour’s Specialization in
Genetics
The University of Western Ontario
London, Ontario, Canada
2011-2016 M.Sc. in Biochemistry

Honours and
Awards:

Travel Award, Children’s Health Research Institute, London,
Ontario, Canada
2015
Travel Award, Department of Paediatrics, The University of
Western Ontario, London, Ontario, Canada
2015
Best Oral Presentation, Annual Paediatrics Research Day,
Children’s Health Research Institute, London, Ontario,
Canada
2015
Lawson Health Research Institute Studentship, Lawson
Health Research Institute Internal Research Fund, London,
Ontario, Canada
2014
Travel Award, Joint meeting of the 20th Biennial Meeting of
the International Society for Developmental Neuroscience
and the 5th Annual NeuroDevNet Brain Development
Conference, Montreal, Quebec, Canada
2014
The Jonathan and Joshua Memorial Graduate Scholarship,
Schulich School of Medicine and Dentistry, The University of
Western Ontario, London, Ontario, Canada
2014

115

Best Poster Presentation, Southern Ontario Neuroscience
Association Annual Meeting, London, Ontario, Canada
2014
Best Poster Presentation, Annual Paediatrics Research
Day, Children’s Health Research Institute, London, Ontario,
Canada
2012
Department of Paediatrics Graduate Studentship, Children’s
Health Research Institute, London, Ontario, Canada
2011
Department of Paediatrics Summer Studentship, Children’s
Health Research Institute, London, Ontario, Canada
2011
Western Graduate Research Scholarship, The University of
Western Ontario, London, Ontario, Canada
2011-2016
Related Work
Experience

Summer Research Student
Children’s Health Research Institute, London, Ontario,
Canada
2011
Research Associate, The University of Western Ontario,
London, Ontario, Canada
2009-2011

Publications
LA Watson, L Solomon, J Ruizhe, Y Jiang, M Edwards, K Shin-ya, F Beier, NG
Bérubé. (2013). Atrx deficiency induces telomere dysfunction, endocrine defects,
and reduced life span. J. Clin. Invest. 123(5): p.2049-20634
Poster Presentations
MW Edwards, Y Jiang, NG Bérubé. Regulation of CNS myelination by the ATRX
chromatin remodeling protein. The Society for Neuroscience 45th Annual
Meeting: Neuroscience 2015, October 2015, Chicago, Illinois, U.S.A
MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. London Health Research Day, March 2015, London, Ontario,
Canada

116

MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. Joint Meeting of the 20th Biennial Meeting of the International
Society for Developmental Neuroscience and the 5th Annual NeuroDevNet Brain
Development Conference, July 2014, Montreal, Quebec, Canada
MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. The 2nd Canadian Conference on Epigenetics, June 2014, London,
Ontario, Canada
MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. Developmental Biology Research Day, May 2014, London, Ontario,
Canada
MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. Annual Paediatrics Research Day, May 2014, London, Ontario,
Canada
MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. Southern Ontario Neuroscience Association Annual Meeting, May
2014, London, Ontario, Canada
MW Edwards, Y Jiang, NG Bérubé. Loss of ATRX causes hypomyelination in the
mouse CNS. London Health Research Day, March 2014, London, Ontario,
Canada
MW Edwards, Y Jiang, B Sutherland, NG Bérubé. Effects of ATRX deficiency on
myelin formation in the CNS. Developmental Biology Research Day, May 2013,
London, Ontario, Canada
MW Edwards, Y Jiang, B Sutherland, NG Bérubé. Effects of ATRX deficiency on
myelin formation in the CNS. Annual Paediatrics Research Day, May 2013,
London, Ontario, Canada
MW Edwards, Y Jiang, B Sutherland, NG Bérubé. Effects of ATRX deficiency on
myelin formation in the CNS. London Health Research Day, March 2013,
London, Ontario, Canada
MW Edwards, Y Jiang, NG Bérubé. Effects of the ATR-X syndrome protein on
brain myelination. Developmental Biology Research Day, May 2012, London,
Ontario, Canada
MW Edwards, Y Jiang, NG Bérubé. Effects of the ATR-X syndrome protein on
brain myelination. Annual Paediatrics Research Day, May 2012, London,
Ontario, Canada

117

MW Edwards, Y Jiang, NG Bérubé. Effects of the ATR-X syndrome protein on
brain myelination. Lawson Research Day, March 2012, London, Ontario, Canada
MW Edwards, AM Laliberté, CML Hutnik, KA Hill. Extracellular matrix remodelling
in the retina of the harlequin (hq) mouse as a possible mechanism for human
age-related retinal degeneration. Centre for Population, Health and Aging 8th
Annual Interdisciplinary Research Event, May 2011, The University of Western
Ontario, London, Ontario, Canada
MW Edwards, AM Laliberté, CML Hutnik, KA Hill. Extracellular matrix remodelling
in the retina of the harlequin (hq) mouse as a possible mechanism for human
age-related retinal degeneration. Lawson Research Day, March 2011, London,
Ontario, Canada
Oral Presentations
MW Edwards, Y Jiang, NG Bérubé. Loss of the ATRX chromatin remodeling
protein results in hypomyelination in the mouse CNS. Developmental Biology
Research Day, June 2015, London, Ontario, Canada
MW Edwards, Y Jiang, NG Bérubé. Loss of the ATRX chromatin remodeling
protein results in hypomyelination in the mouse CNS. Annual Paediatrics
Research Day, May 2015, London, Ontario, Canada
MW Edwards, AM Laliberté, CML Hutnik, KA Hill. Retinal degeneration in the
harlequin (hq) mouse is characterized by early gene expression changes with
associated nuclear displacement. Ontario Biology Day, March 2011, Wilfred
Laurier University, Waterloo, Ontario, Canada
M Edwards, AM Laliberté, TC MacPherson, CML Hutnik, KA Hill. The power of
animal mimics of human eye disease: in vivo imaging, post-mortem histology and
molecular biomarkers. Annual Ophthalmology Research Day, November 2010,
London, Ontario, Canada

